CD137 ligand trigger in phospholipid signalling cascade in a monocyte cell line by H'NG SHIAU CHEN
  
CD137 LIGAND TRIGGER  
IN PHOSPHOLIPID SIGNALLING CASCADE  




















CD137 LIGAND TRIGGER IN PHOSPHOLIPID 




H’NG SHIAU CHEN 
(B. Science with Merit, NUS) 
 
 
A THESIS SUBMITTED FOR  
THE DEGREE OF MASTER OF SCIENCE 
 
 
DEPARTMENT OF PHYSIOLOGY 
YONG LOO LIN SCHOOL OF MEDICINE 







I hereby declare that this thesis is my original work and it has been 
written by me in its entirety. I have duly acknowledged all the sources of 
information which have been used in the thesis. 





______________________    
H’NG SHIAU CHEN 





First and foremost, I would like to thank Department of Physiology, 
Yong Loo Lin School Of Medicine, National University of Singapore, 
especially to the Head of Department, A/P Soong Tuck Wah, for the 
opportunity to do my part time graduate studies in the department. Without the 
department’s support, I would not have realized my dream to pursue a higher 
degree in research.  
I would like to express my deepest gratitude to my supervisor, A/P 
Schwarz Herbert, for supporting me in completion of the project. I would like 
to thank him for his guidance, advice and patience throughout this project. I 
will not forget his words of encouragement and impromptu discussions 
whenever I needed one. I am also grateful to him for proof-reading my thesis. 
I also would like to thank all the past and present lab mates for all the 
help and assistance rendered to me throughout the studies especially Jane Pang, 
Dr. Shaqireen Kwajah, Dr. Shao Zhe, Dr. Angela Moh, Ho Weng Tong, Koh 
Liang Kai, Cheng Cheong Kin and Zulkarnain Harfuddin. I would like to 
thank A/P Lam Yulin and Dr. Wong Lingkai for providing compound 5c for 
my project. 
Special thanks go to Dr. Sheryl Tan and Dr. Wang Binbin for their 
friendships and supports throughout the years. I truly treasure the memories 
and wisdom shared in science and in life. I would like to thank Chong Oi 
Khuan, Teoh Chun Ming, Chin Chin Yein and Qiao Yong Kang for their 
encouragement and friendships.  
 I would like to extend my appreciation to Dr Wong Boon Seng and 
Lim Mei Li for their kind understanding and support in the final year of my 
iv 
 
studies. I also wish to extend my warmest thanks to all colleagues in the 
Department Of Physiology for their understanding and assistance rendered to 
me throughout my studies.    
Last but not least, I would like to thank my parents, my siblings, my 
husband and my daughter for the love, patience and support. I could not have 
done this without them. This thesis is dedicated to my parents and my husband 





TABLE OF CONTENTS 
 PAGE 
TITLE PAGE i 
DECLARATION  ii 
ACKNOWLEDGEMENTS iii 
TABLE OF CONTENTS v 
SUMMARY ix 
LIST OF TABLES xi 
LIST OF FIGURES xii 




CHAPTER 1 INTRODUCTION      1 
1.1 CD137 And CD137 Ligand Biology 
1.1.1 CD137 Biology 
1.1.2 CD137 Ligand Biology 
1.1.3 Soluble CD137 And CD137 Ligand 
1.1.4 CD137 Ligand Reverse Signalling  
1.1.4.1 CD137 Ligand In Human Monocytes 
1.1.4.2 CD137 Ligand In Human Monocyte-derived Dendritic 
Cell  
1.1.4.3 CD137 Ligand In Murine Myeloid Cells And 
Macrophages  
1.1.4.4 CD137 Ligand In Osteoclastogenesis 
vi 
 
1.1.5 CD137 And Its Ligand In Inflammation 
1.2 Sphingolipids 
1.2.1 Sphingosine Metabolism Pathway 
1.2.2 Sphingosine Kinase 
1.2.3 Sphingosine Kinase Inhibitors 
1.2.4 Natural Products As Sphingosine Kinase Inhibitors 
1.2.5 Sphingosine Kinase In Inflammation 
1.3 Phospholipase D, Protein Kinase C And Sphingosine Kinase 
1.4 Monocytes/Macrophages And Chemokines 
1.4.1 Chemokines In Diseases 
1.5 Rationale And Aims Of The Project 
 
CHAPTER 2 MATERIALS AND METHODS    48 
2.1 Reagents And Chemicals 
2.2 Solutions And Buffers 
2.3 Cell Line 
2.4 Stimulation Of Cells 
2.4.1 Protein Immobilization  
2.4.2 CD137 Ligand Stimulation 
2.5 Preparation And Treatment Of Inhibitors 
2.5.1 Preparation Of DMS And Compound 5c 
2.5.2 Preparation Of Bisindolylmaleimide I 
2.5.3 Sphingosine Kinase Inhibition  
2.5.4 Phospholipase D Inhibition 
2.5.5 Protein Kinase C Inhibition 
vii 
 
2.6 Morphological Changes 
2.7 Preparation Of Cell Extracts 
2.8 Western Blot 
2.9 Measurement Of Sphingosine Kinase Activity Using Fluorometric 
Assay 
2.10 Preparation Of Supernatants 




CHAPTER 3 RESULTS       57 
3.1 CD137L Induced Adherence And Morphological Changes In THP-1 
Cells 
3.2 Involvement Of Sphingosine Kinases, Not Phospholipase D, In 
CD137L-Activated Cells  
3.3 Expression Of Sphingosine Kinase 1 In Monocytic Cell Lines 
3.4 CD137L Signalling Activates Sphingosine Kinase 1 
3.5 CD137L Signalling Does Not Induce Sphingosine Kinase 1 Protein  
3.6 Involvement Of Sphingosine Kinase In CD137L-Induced 
Inflammatory Chemokines Production 
3.7 Involvement Of Protein Kinase C In CD137 Ligand Signalling 
 
CHAPTER 4 DISCUSSION      77 




4.2 Involvement Of Sphingosine Kinases, Not Phospholipase D, In CD137 
Ligand-Activated Cells  
4.3 CD137L Does Not Induce Expression Of Sphingosine Kinase 1 
4.4 CD137 Ligand Signalling Activates Sphingosine Kinase 1 
4.5 Involvement Of Sphingosine Kinases In CD137 Ligand-Induced 
Inflammatory Chemokines Production 
4.6 Involvement Of Protein Kinase C In CD137 Ligand Signalling 
4.7 Cross-linking Is Needed To Activate The CD137L Signalling Pathway 
4.8 Controls In The Experiment 
 
CHAPTER 5 CONCLUSION      89 
 
CHAPTER 6 FUTURE DIRECTION     92 
 
REFERENCE        94 
 









CD137 and its ligand (CD137L) are members of tumour necrosis 
factor (TNF) receptor and TNF superfamily, respectively, in which 
bidirectional signalling has been shown. CD137L is a transmembrane protein 
that is capable of transducing a downstream signalling pathway in the cells 
expressing it. CD137L is constitutively expressed by monocytes which are 
very pivotal in the host defence against infections.  Monocytes circulating in 
the bloodstream migrate to inflammation sites under the guidance of 
chemokine gradients to support immune responses. A chemokine gradient is 
formed by the local release of chemokine at the inflamed tissues and its 
diffusion away from the site. Chemokine receptors on immune cells and 
chemokine gradients originating at the inflammation site are equally important 
in leukocyte homing. Sphingolipid metabolites have emerged as important 
second messengers, mediating signalling pathways triggered in immune cells. 
Sphingosine kinase (SphK) is implicated in inflammation, autoimmune 
diseases, allergies and cancer development. SphK phosphorylates sphingosine 
to yield sphingosine-1-phoshate (S1P) which acts as an intracellular second 
messenger in the cells, or as a ligand to S1P receptor (S1PR) after being 
transported out of the cells.  
In this study, we found that CD137L stimulation in the monocytic cell 
line THP-1 induced activation of SphK, which reached its peak activity at 10 
minutes and remained active up to 30 minutes after stimulation when 
compared to the basal level of kinase activity. SphK is found to mediate the 
production of inflammatory chemokines, e.g. interleukin 8 (IL-8) by the 
CD137L activated cells. The most commonly used pharmacological SphK 
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inhibitor, N, N-Dimethylsphingosine (DMS), and the SphK1 specific inhibitor, 
compound 5c, are found to inhibit the secretion of the inflammatory 
chemokine IL-8. CD137L activated THP-1 cells also produced other 
inflammatory chemokines such as monocyte chemoattractant protein 1 (MCP-
1), macrophage inflammatory protein (MIP)-1α and MIP-1β, which are 
important in leukocyte homing. MCP-1 and its receptor on monocytes, CCR2, 
are proven to play an important role in recruiting monocytes to the inflamed 
tissues during bacterial infection. The secretions of MCP-1, MIP-1α and MIP-
1β were also inhibited by DMS and 5c. This study shows that SphK plays a 
role in the signal transduction induced by CD137L, and is pivotal in the 
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1.1 CD137 And CD137 Ligand Biology 
1.1.1 CD137 Biology 
CD137 (also known as “induced by lymphocyte activation” (ILA), 4-
1BB, TNFRSF9) is a member of tumour necrosis factor receptor superfamily 
(TNFRSF), and has been identified as T cell costimulatory molecule (Croft, 
2003a, b). In 1996, at the 6
th
 International Workshop on Human Leukocyte 
Differentiation Antigens held in Kobe, Japan, ILA or 4-1BB has received its 
nomenclature as CD137 (Kishimoto et al., 1997). 
CD137 was first identified as ILA in 1995 as a homologue to murine 
4-1BB, found primarily in activated T and B lymphocytes, monocytes and 
non-lymphoid cell types such as epithelial and hepatoma cells (Schwarz et al., 
1995). It was found to be the human counterpart of murine 4-1BB with 73.6% 
similarity and 59.6% identity to murine 4-1BB (Schwarz et al., 1995). CD137 
is a type 1 transmembrane protein with three cysteine-rich repeats at the 
extracellular part, similar to other nerve growth factor/tumour necrosis factor 
(NGF/TNF) superfamily members (Schwarz et al., 1995). Human CD137 is 
found to be on chromosome 1p36, which also harbours genes of other TNFSF 
such as CD30 and OX40 and also a cluster of genes related to malignant 
diseases such as hematopoietic malignancies (Schwarz et al., 1997). 
It has been shown that this protein expression is inducible upon 
activation in T lymphocytes, B lymphocytes, monocytes (Schwarz et al., 1995), 
natural killer (NK) cells, NKT cells, mast cells, neutrophils, dendritic cells 
(DC), endothelial cells, eosinophils and osteoclast precursors (Croft, 2009; 
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Croft et al., 2012). CD137 messenger ribonucleic acid (mRNA) and protein 
are also found present in astrocytes, neurons and microglia; CD137 expression 
is upregulated by fibroblast growth factor-2 (FGF-2) in neuron and astrocytes 
(Reali et al., 2003). CD137 is not expressed in the resting lymphocytes 
(Kienzle and von Kempis, 2000). In T lymphocytes, CD137 is said to be 
upregulated within 24 hours by stimulated T cells and to play a major role in 
costimulating T cells and sustaining the T cell response from a few hours to 
several days (Croft, 2003a, 2009). CD137 is constitutively expressed on 
monocytes and upon activation, it can induce monocyte activation. CD137 
stimulated monocytes induce production of TNF-α, interleukin-8 (IL-8) but 
decrease production of IL-10 (Kienzle and von Kempis, 2000). 
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1.1.2 CD137 Ligand Biology 
CD137 ligand (CD137L) (also known as 4-1BBL, TNFSF9) is 
identified as a type II transmembrane protein since its carboxy-terminal 
domain is on the extracellular side (Alderson et al., 1994). Human CD137L is 
located on chromosome 19 in the region 19p13.3, and only shares about 36% 
amino acid sequence homology with murine CD137L, and even the cysteine 
residues are not conserved between these two species (Alderson et al., 1994). 
It has been speculated that there may be alternative ligands for CD137 
(Alderson et al., 1994).  
CD137L is expressed by antigen presenting cells (APC) such as DCs, 
B cells, macrophages, and by T cells, NK cells, mast cells (Nishimoto et al., 
2005), hematopoietic progenitors and osteoclast precursors (Croft, 2009; Croft 
et al., 2012) and during inflammation in non-immune cells such as endothelial 
cells and smooth muscle cells (Croft, 2009). CD137L is constitutively 
expressed by monocytes/macrophages but inducible in T lymphocytes 
(Alderson et al., 1994; Ju et al., 2003; Schwarz, 2005). Ectopically expressed 
CD137L induces the proliferation of T lymphocytes (Alderson et al., 1994).  
CD137L is also found in cells of the central nervous system (CNS) 
such as astrocytes and neurons, but not detected in microglia, and its 
expressions is not affected by FGF-2 treatment (Reali et al., 2003). However, 
recently, a report showed that CD137L is expressed in microglia cell lines and 
primary microglia (Yeo et al., 2012).  
As a transmembrane protein, CD137L can act as a co-receptor, and 
upon binding to CD137, CD137L too can trigger signalling cascade 
downstream in the cells expressing it (Figure A) (Shao and Schwarz, 2011). 
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This is a unique feature of many receptor-ligand pairs in TNF superfamily that 
exhibits bidirectional signalling such as OX40L and CD40L (Lotz et al., 1996; 
Schwarz, 2005; Thum et al., 2009).  
CD137L is also found to be highly expressed in cancer cell lines and 
stimulation of CD137L on the tumour cell lines induces release of IL-8 but not 
IL-6, IL-10, IL-12, TNF-α or transforming growth factor β (TGF-β) (Salih et 
al., 2000).    
Activation of CD137 on T lymphocytes induces activation and 
proliferation of the lymphocytes; however, activation of its ligand by CD137 
protein induces expression of CD95, inhibits proliferation and enhances 
apoptosis via activation induced cell death (AICD) in the lymphocytes (Lotz et 
al., 1996; Michel et al., 1999; Schwarz et al., 1996). CD137 stimulation on B 
lymphocytes induces apoptosis in the cells too (Kienzle and von Kempis, 
2000). This is thought to be the regulation role displayed by CD137 and its 
ligand in the immune system.  
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Figure A. Bidirectional signal transduction. CD137 and its ligand are capable 
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1.1.3 Soluble CD137 And CD137 Ligand 
Soluble CD137 (sCD137) and its ligand (sCD137L) have been 
reported in inflammatory diseases as well as cancers. sCD137 is released by 
activated lymphocytes through alternative splicing (Michel et al., 1998). The 
level of the protein has been reported to be low in the sera of healthy control 
donors as compared to rheumatoid arthritis (RA) patients (Jung et al., 2004; 
Michel et al., 1998), systemic lupus erythematosus (SLE) and Behcet’s disease 
(BD) (Jung et al., 2004), leukaemia and lymphoma patients (Furtner et al., 
2005). The level of sCD137 is reported to correlate to the severity of the 
disease, and also to the degree of AICD induced in lymphocytes (Furtner et al., 
2005; Jung et al., 2004; Michel and Schwarz, 2000). The soluble form of this 
molecule provides a negative feedback loop to the immune system to regulate 
the immune response as sCD137 is found to be expressed at later stage of the 
stimulation as compared to membrane bound CD137 (Michel and Schwarz, 
2000).  
sCD137L too is elevated in SLE, BD (Jung et al., 2004), multiple 
sclerosis (MS) (Liu et al., 2006), Non-Hodgkin lymphoma (NHL), 
myelodysplastic syndrome and acute myeloid leukaemia (AML) (Salih et al., 
2001). sCD137L is found to be cleaved from the membrane bound ligand, and 
remains functionally active in the system, as it would stimulate T lymphocytes 
to release IL-2 and interferon-γ (IFN-γ) (Salih et al., 2000). There is no 
inhibition of the T cells proliferation by the anti-CD137L antibody indicating 
that this may be just a regulatory role played by CD137L (Liu et al., 2006).  
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1.1.4 CD137 Ligand Reverse Signalling  
1.1.4.1 CD137 Ligand In Human Monocytes 
CD137L is constitutively expressed on human monocytes/ 
macrophages (Alderson et al., 1994; Ju et al., 2003; Schwarz, 2005). Cross-
linking of CD137L is required to trigger the signalling downstream in the cells 
because soluble antibody or recombinant CD137 protein do not activate the 
cells (Kang et al., 2007; Langstein et al., 1998; Langstein et al., 1999; 
Langstein and Schwarz, 1999; Yeo et al., 2012). CD137L has been identified 
as the novel stimulator that induces proliferation of monocytes (Ju et al., 2003; 
Langstein et al., 2000; Langstein et al., 1999). CD137L stimulation can also 
drive the cells into apoptosis (Langstein et al., 1999). However, a higher rate 
of proliferation that is simultaneously induced compensates the rate of 
apoptosis (Langstein et al., 1999). The lifespan of monocytes can be prolonged 
by the activation of CD137L via release of macrophage-colony stimulating 
factor (M-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF) 
and IL-3 (Langstein et al., 2000; Langstein et al., 1999; Langstein and 
Schwarz, 1999). M-CSF also acts as the essential factor to support monocyte 
proliferation because neutralizing anti-M-CSF antibodies greatly reduced the 
viability of the cell (Langstein et al., 1999; Langstein and Schwarz, 1999). IL-
8 release, morphological changes and adhesiveness of the cells are indicators 
for the activation by CD137L (Langstein et al., 2000; Langstein et al., 1998; 
Langstein and Schwarz, 1999). The effects induced by CD137L in monocytes 
are comparable to that lipopolysaccharide (LPS), a potent monocyte activator, 
and CD137L can further augment the effects of LPS by inducing higher IL-8, 
M-CSF and myc expression (Langstein et al., 2000). CD137L stimulation has 
7
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been found to increase the release of IL-6, IL-8, TNF-α and to inhibit IL-10 
(Langstein et al., 1998). The expression of intracellular adhesion molecule 
(ICAM) is also induced, indicating the differentiation of monocyte to 
macrophages (Langstein et al., 1998). 
The CD137L activated signalling pathway induces the activation of 
tyrosine kinase, mitogen-activated protein kinase (MAPK) p38 and 
extracellular signal-regulated protein kinases 1/2 (ERK1/2) in monocytes 
(Söllner et al., 2007). The CD137L-activated  IL-8 production in monocytes is 
mediated by Src kinase, MAPK p38, ERK1/2, phosphoinositide 3-kinase (PI3-
K), protein kinase A (PKA) but not protein kinase C (PKC) (Söllner et al., 
2007). PI3-K is shown to be upstream of ERK1/2 as Wortmannin effectively 
inhibited the phosphorylation of ERK1/2 (Söllner et al., 2007). In the 
downstream signalling cascade, nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) is shown to be activated by CD137L in monocytes 
(Ju et al., 2009). 
CD137L engagement on monocytes induces monocytes to migrate to 
the site where CD137 is strongly expressed such as to the inflammatory tissues 
(Drenkard et al., 2007). CD137L is also shown to increase the number of 
monocytes rolling and adhering to ICAM-1 and E-selectin in a flow chamber 
simulating in vivo flow of blood in blood vessels (Quek et al., 2010).   
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1.1.4.2 CD137 Ligand In Human Monocyte-derived Dendritic Cell  
CD137L signalling also induces maturation of DC upon activation by 
the receptor (Ju et al., 2009; Lippert et al., 2008). CD137L activation 
upregulates the DC maturation marker CD83, the costimulatory molecules 
CD86 and HLA-DR on monocyte-derived dendritic cells (MoDC) which are 
also termed as classical DC (Ju et al., 2009; Lippert et al., 2008). The 
chemokine receptors, CXC-chemokine receptor 4 (CXCR4) and CC-
chemokine receptor 7 (CCR7), are also upregulated to mediate migration of 
DC (Lippert et al., 2008). TNF-α is shown to be important to drive the DC 
maturation as its neutralization suppressed the expression of CD83 (Lippert et 
al., 2008). Secretion of IL-12p70 and IFN-γ but not IL-10 upon tetanus toxoid 
and CD137L activation, suggests that the effects of CD137L signalling are 
driving Th cell differentiation to Th1 cells (Ju et al., 2009; Lippert et al., 2008).             
CD137L does not only drive the maturation of classical DC, it has also 
been shown to induce differentiation of monocytes into a different subset of 
DC (Kwajah M M and Schwarz, 2010). The CD137L-induced DCs are shown 
to be different from classical DC. CD137L-induced DCs upregulate CCR7 
expression; however, the expression of CXCR4 is downregulated (Kwajah M 
M and Schwarz, 2010). The cells produce low level of IL-10 and high levels 
of IL-23 as compared to classic DC. CD137L-induced DCs do not secrete IL-
12, and do not express DC-specific intercellular adhesion molecule-3-grabbing 
non-integrin (DC-SIGN) or CD1a (Kwajah M M and Schwarz, 2010). 
Differentiation of monocytes to DC by CD137L signalling inhibits NF-κB 
(Kwajah M M and Schwarz, 2010). However, another study demonstrated that 
9
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CD137L-matured DCs induce the translocation of the NF-κB from cytosol to 
nucleus (Ju et al., 2009). 
However, there is a species difference reported recently according to 
which activation of CD137L signalling in murine immature classical DC did 
not induce maturation as compared to  human immature classical DC (Tang et 
al., 2011). CD137L stimulated murine monocytes were shown to induce 
activation of the cells through the morphological changes and increased 
adherence of the cells onto the plate, but it did not induce expression of CD80 
and CD86 (Tang et al., 2011) as reported by others for human immature DC 
(Ju et al., 2009; Lippert et al., 2008). The activation of CD137L in murine 
classical DC has the opposite effect compared to human classical DC, because 
IL-10 is produced instead of IL-12, and because addition of LPS further 
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1.1.4.3 CD137 Ligand In Murine Myeloid Cells And Macrophages  
Another interesting finding is that CD137L is required to sustain the 
release of TNF-α, and that this activity of CD137L is independent of its 
receptor, CD137, but dependent on Toll-like receptor-4 (TLR4) (Kang et al., 
2007). The cytoplasmic domain of CD137L and the TLR4 intracellular 
domain are found to associate. Surprisingly, myeloid differentiation primary 
response gene (MyD) 88 and TIR-domain-containing adapter-inducing 
interferon-β (TRIF) are not needed in the CD137L-TLR4 mediated TNF-α 
induction (Kang et al., 2007). LPS stimulates the expression of CD137L in 
macrophages, and this induction is dependent on TLR4, MyD88 and TRIF and 
is mediated by MAPK p38, c-Jun N-terminal kinases (JNK), MEK (Kang et 
al., 2007). CD137L activates the cAMP response element binding (CREB) and 
CCAAT-enhancer-binding proteins (C/EBP), which are also mediating the 
release of TNF-α upon LPS stimulation (Kang et al., 2007). MAPK p38, 
ERK1/2 and JNK are phosphorylated but not NF-κB upon CD137L 
stimulation, which then induce the production of TNFα in macrophages (Kang 
et al., 2007). Deletion of CD137L does not affect the activation of NF-κB, 
activator protein-1 (AP-1), JNK, ERK, and p38 in LPS stimulation (Kang et 
al., 2007). Another group has shown that CD137L stimulation in RAW264.7 
cells is reported to be independent of MAPK p38, ERK1/2, JNK, NF-κB and 
CREB (Kim et al., 2009) which contradicts work done by Söllner et al. (2008) 
and Kang et al. (2007) (Kang et al., 2007; Söllner et al., 2007). Kim et al. 
(2009) showed that CD137L signalling induces the phosphorylation of 
tyrosine kinase, Akt (also known as protein kinase B) and p70s6K, indicating 
the involvement of PI3-K and mammalian target of rapamycin (mTOR) in the 
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signalling cascade (Kim et al., 2009). However, bone marrow-derived 
macrophages (BMM) show responses similar to those observed in monocytes 
i.e. enhanced adherence (Kim et al., 2009; Langstein et al., 2000; Söllner et al., 
2007) and increased levels of ICAM-1 (Kim et al., 2009; Langstein et al., 
1998). Activation of CD137L in BMM increases the levels of IL-1β, IL-6 and 
M-CSF production (Kim et al., 2009). RAW264.7 cells also has increased 
adherence, proliferation, IL-1β, IL-1 receptor antagonist (IL-1RA), IL-6, 
cyclooxygenase 2 (COX-2), tenascin C (TN-C), neuropeptide Y (NPY) and 
M-CSF mRNA in response to CD137L signalling (Kim et al., 2009). CD137L 
enhances the effect of LPS as reported in monocytes (Langstein et al., 2000) 
and of M-CSF in macrophages (Kim et al., 2009). Two independent signalling 
pathways were proposed based on the different effects implicated by 
Wortmannin and LY294002 (Kim et al., 2009). Akt is proposed to be the 
mediator in the release of IL-1β, which may involve a tyrosine kinase while 
the mTOR pathway is suggested to play a role in the survival and proliferation 
of macrophages through the release of M-CSF (Kim et al., 2009).   
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1.1.4.4 CD137 Ligand In Osteoclastogenesis 
In studies on bone formation, CD137L reverse signalling is shown to 
play a role in osteoclastogenesis in vitro and in vivo, through the use of 
CD137
-/-
 mice, and cell lines (Saito et al., 2004; Shin et al., 2006a; Shin et al., 
2006b; Yang et al., 2008).  
CD137L stimulation inhibits osteoclastogenesis induced by M-
CSF/receptor activator of nuclear factor-κB ligand (RANKL) (Saito et al., 
2004; Shin et al., 2006a; Shin et al., 2006b). Wild type (WT) mice have high 
release of IFN-β, which enhances the release of IL-10 that leads to slower 
osteoclast formation as compared to CD137
-/-
 mice (Shin et al., 2006a; Shin et 
al., 2006b). CD137, but not CD137L, protein expression was shown to 
increase in osteoblasts that had been infected by bacteria (Saito et al., 2004). 
CD137L was detected on the macrophage like cell line (RAW264.7) and on 
bone marrow cells (Saito et al., 2004). CD137L too induced proliferation and 
the release of M-CSF in primary bone marrow cells and BMM (Saito et al., 
2004). CD137L activation inhibited the formation of osteoclasts in bone 
marrow (Saito et al., 2004). Casein kinase 1 (CK1) may be involved in this 
inhibition because the casein kinase 1 inhibitor (CKI7) suppressed the 
osteoclastogenesis inhibition by CD137L, and also the proliferation of the 
cells (Saito et al., 2004). The RANKL signalling pathway induces the 
phosphorylation of MAPK p44/42, p38, JNK, NF-κB inhibitor (I-κB) but 
CD137L activation did not affect the phosphorylation of these molecules 
(Saito et al., 2004). CD137L only suppresses the activation of Akt and nuclear 
factor of activated T cells-2 (NFAT-2) by RANKL (Saito et al., 2004).  
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Despite all three reports describing an inhibitory role of CD137L in 
osteoclastogenesis, recently another group showed that CD137
-/-
 mice have 
increased bone mass and a decreased formation of osteoclasts from BMM 
(Yang et al., 2008). Phosphorylation of JNK and p38 was lower and induction 
of c-Fos and NFAT-cytoplasmic 1 (NFAT-c1) was reduced in CD137
-/-
 as 
compared to WT BMM. Again, in CD137
-/-
 mice the phosphorylation state of 
MAPK p44/42 and I-κB were not affected (Yang et al., 2008). The difference 
in these reports could be due to the differences in the stimulation of the 
primary cells in the culture.  
  
14
CHAPTER 1: INTRODUCTION 
 
1.1.5 CD137 And Its Ligand In Inflammation 
More and more evidences have emerged showing that TNF and TNFR 
superfamily members are involved in inflammatory and autoimmune diseases 
such as sepsis, RA, atherosclerosis, myocarditis, graft-versus-host disease 
(GVHD), colitis (Croft et al., 2012)  and MS (Liu et al., 2006).  
CD137 is strongly expressed on the wall of blood vessels in inflamed 
tissues such as the skin in vasculitis, the nasal septum in rhinitis, the colon of 
Crohn’s disease patients and the thyroid gland of Grave’s disease patients 
(Broll et al., 2001; Drenkard et al., 2007). CD137 expression on the 
endothelial cells is induced by TNF and IL-1 (Drenkard et al., 2007; Quek et 
al., 2010). Monocytes migrate to sites where CD137 is expressed as is shown 
by the infiltration of monocytes into the matrigel containing CD137-Fc protein 
in mice (Drenkard et al., 2007). Monocytes could be activated by the CD137 
on the endothelial cells, causing extravasation of the monocytes into tissues 
(Broll et al., 2001). Monocytes roll and adhere to a flow chamber coated with 
CD137-Fc protein, a process which is mediated by ICAM-1 and E-selectin 
(Quek et al., 2010).  
CD137 protein expression increases during experimental autoimmune 
encephalomyelitis (EAE) in the CNS (Yeo et al., 2012). EAE, a murine model 
of human MS, is an autoimmune disease that is characterized by the 
destruction of the myelin sheats caused by inflammation, and subsequently the 
death of neurons. Activation of microglia through CD137L leads to the 
production of reactive oxygen species (ROS) which in turn induces apoptosis 
of the oligodendrocytes that contributes to the disease (Yeo et al., 2012). 
CD137L activation induces pro-inflammatory cytokines such as TNF, IL-1, 
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IL-6, IL-12, and monocyte chemotactic protein-1 (MCP-1), and it also induces 
matrix metalloproteinase (MMP)-9 and soluble ICAM release from microglia 
(Yeo et al., 2012).  In MS patients, membrane bound CD137L on CD14
+
 
monocytes and sCD137L were found higher in the plasma (Liu et al., 2006). 
CD137L did not inhibit the proliferation of myelin basic protein-reactive T 
cells. The release of soluble forms of CD137L could be a way of regulation of 
the immune response in the patients (Liu et al., 2006).  
In Crohn’s disease, CD137 is expressed on the lamina propria in the 
inflamed tissue, and high levels of CDL137L are present in the mesenterial 
lymph nodes. Agonistic antibody against CD137 causes an elevated level of 
IFN-γ production. This study is suggesting that interaction of CD137 with its 
ligand may contribute to the chronic inflammation in patients (Maerten et al., 
2004).   
In human atherosclerosis, CD137 is also highly expressed on T cells, 
endothelial cells, and smooth muscle cells, while CD137L is found on CD68
+
 
macrophages found in the atherosclerotic lesions. Expression of CD137 on 
endothelial cells is enhanced by inflammatory cytokines (TNF-α, IL-1β and 
IFN-γ) (Olofsson et al., 2008). CD137 activation also induces vascular cell 
adhesion molecule (VCAM)-1 and ICAM-1 expression on the endothelial 
cells and decreases the proliferation of smooth muscle cells (Olofsson et al., 
2008).    
In RA patients, sCD137 and sCD137L are released into the sera of the 
patients, and the levels in the sera correlate closely with the rheumatoid factor 
(RF) and Erythro Sedimentation Rate (ESR), a non-specific biomarker of 
inflammation, values (Jung et al., 2004; Michel et al., 1998). RA is a type of 
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autoimmune disease that is characterized by a chronic inflammation at the 
synovial tissues of the joint that eventually leads to the destruction of the joint, 
including cartilages and bones (Lai et al., 2012). CD137L activation inhibits 
osteoclastogenesis and it was speculated that CD137L may play a role in the 
bone and cartilages destruction in final stage of RA (Saito et al., 2004; Shin et 
al., 2006a; Shin et al., 2006b; Yang et al., 2008).  
In a murine model of acute kidney ischemia-reperfusion injury (IRI), 
CD137 is expressed on NK cells and CD137L on the tubular epithelial cells 
(TECs) (Kim et al., 2012). NK cells activated CD137L reverse signalling in 
TECs, leading to the production of chemokine ligands, CXCL-1 and CXCL-2, 
in WT mice. Both the chemokine ligands are responsible for the recruitment of 
neutrophils into the inflamed kidney tissues during IRI (Kim et al., 2012). NF-
κB is activated by CD137 ligand activation in the TEC. Upregulation of 
CXCL-1 and CXCL-2 is mediated by p38 and JNK. Hence, CD137 and its 
ligand are involved in mediating the infiltration of the neutrophils and 
contribute to the inflammation of IRI model (Kim et al., 2012). 
CD137L, alongside with secretion of macrophage inflammatory 
protein (MIP)-1α and MIP-1β, is enhanced in peripheral blood mononuclear 
cell (PBMC) during chronic heart failure (CHF) (Yndestad et al., 2002).  
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1.2 Sphingolipids 
Sphingolipid metabolites have emerged as important second 
messengers, mediating signalling pathways triggered in immune cells 
including monocytes, macrophages, neutrophils and mast cells (Olivera and 
Spiegel, 2001b). Sphingosine kinase (SphK) is implicated in inflammation, 
autoimmune diseases, allergies and cancer development (Kee et al., 2005). 
SphK, in different types of cells, by different kinds of agonists, can initiate 
different signalling pathways through activation of several important second 
messengers including sphingosine-1-phosphate (S1P), PKC, ERK1/2, calcium 
ions (Ca
2+
), and phospholipase D (PLD) (Snider et al., 2010). SphK is 
activated by a number of stimuli including platelet-derived growth factor 
(PDGF), NGF, vascular endothelial growth factor (VEGF), insulin-like growth 
factor (IGF), IGF binding protein-3 (IGFBP-3), lysophosphatidic acid (LPA), 
LPS, complement 5a (C5a), TNF-α, epidermal growth factor (EGF), activated 
immunoglobulin receptors (Fragment crystallizable (Fc)-γ receptor 1 (FcγR1) 
and FcεR1), acethylcholine (muscarinic agonists) and many more (Olivera and 
Spiegel, 2001b; Snider et al., 2010) 
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1.2.1 Sphingosine Metabolism Pathway 
Sphingomyelin, other than being a major sphingolipid in the plasma 
membrane, is also the main precursor of lipid signalling. In the metabolism 
pathway, sphingomyelin is hydrolysed by sphingomyelinases (SMase) to yield 
ceramide. Ceramide is then degraded by ceramidase to produce sphingosine, 
which is phosphorylated by SphK to yield S1P. In the salvage pathway, S1P 
phosphatase (SPP) can dephosphorylate S1P into sphingosine, and 
sphingosine is converted back to ceramide by ceramide synthase. S1P may 
also be converted into ethanolamine phosphate and hexadecenal irreversibly 
by S1P lyase (Figure B) (Olivera and Spiegel, 2001a, b; Snider et al., 2010; 
Spiegel, 1999).  
Ceramide and sphingosine have been linked to cell death, while their 
downstream molecule, S1P, is important for cell survival. Ceramide and 
sphingosine are generally produced under stress conditions and during 
apoptosis; S1P production is driven by growth factors, leading to proliferation 
and survival. The dynamic balance of ceramide - S1P determines the fate of 
the cell, and is often dubbed as the “sphingolipid rheostat” (Olivera and 
Spiegel, 2001b; Spiegel, 1999). The sphingolipid rheostat has been implicated 
in activating signalling cascades such as activation of calcium release from the 
internal store, activation of MAPK ERK pathway, and activation of AP-1-
mediated transcription factor pathway (Olivera and Spiegel, 2001b).   
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Figure B. Sphingosine metabolism pathway. Sphingomyelin is hydrolysed by 
SMase to yield ceramide. Ceramide is then degraded to sphingosine by 
ceramidase. Sphingosine is phosphorylated by SphK to generate S1P. S1P can 
be either degraded into hexadecanal and phosphoethanolamine irreversibly by 
S1P lyase or dephosphorylated back to sphingosine by S1P phosphatase. 
Sphingosine then is converted back to ceramide by ceramide synthase. 
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1.2.2 Sphingosine Kinase 
The first mammalian SphK, murine SphK1a and SphK1b, was cloned 
and characterized in 1998 (Kohama et al., 1998). Subsequently, in 2000, the 
human SphK1 was cloned and characterized (Melendez et al., 2000; Nava et 
al., 2000). In the same year, 2000, the second isoform of SphK, SphK2, was 
cloned, both in man and mouse (Liu et al., 2000). SphK1 and SphK2 share 80% 
of similarity and 45% identity which includes the putative catalytic domain 
and residues for adenosine triphosphate (ATP) and sphingosine binding 
(Pitman and Pitson, 2010). 
It is now being accepted that the two isoforms of SphK respond 
differently; almost opposite of each other, that activation of SphK1 leads to 
the synthesis of S1P, promoting survival while SphK2 promotes apoptosis 
through production of ceramide (Gangoiti et al., 2010). The opposite actions 
of the two isoforms are speculated to be caused by the different pathways that 
they may use: SphK1 is speculated to phosphorylate sphingosine produced by 
de novo synthesis, and SphK2 phosphorylates the salvaged sphingosine 
(Maceyka et al., 2005). SphK1 reduces ceramide level through 
phosphorylation of sphingosine into S1P, and S1P is degraded irreversibly by 
S1P lyase (Maceyka et al., 2005). Generated S1P may also negatively regulate 
ceramide synthesis (Maceyka et al., 2005). SphK2, on the other hand, may 
utilize the salvaged sphingosine as part of the effort of the cells to conserve 
resources, thus, promoting dephosphorylation of S1P by SPP, yielding 
sphingosine and ceramide (Maceyka et al., 2005).  
SphK1/SphK2 double knockout mice are embryonically lethal from 
severe defects in angiogenesis and neurogenesis but single knockout mice can 
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develop normally, indicating that these two isoforms may play a compensatory 
role in the mice when the other isoform is absent (Pitman and Pitson, 2010).     
SphK1 is ubiquitously expressed in adult tissues mainly in the liver, 
lung, kidney, spleen, skeletal muscles, peripheral blood leukocytes and thymus 
(Melendez et al., 2000; Nava et al., 2000). Through alternative splicing, there 
are three forms of SphK1 namely SphK1a, SphK1b and SphK1c (Orr Gandy 
and Obeid, 2013). SphK1 specifically phosphorylates D-erythro-sphingosine 
and D-erythro-dihydrosphingosine in mammals (Kohama et al., 1998; Olivera 
and Spiegel, 2001b; Pitman and Pitson, 2010). Unlike SphK2, SphK1 does not 
phosphorylate phytosphingosine (Olivera and Spiegel, 2001b). SphK1 is 
generally located in the cytosol of the cells and translocate to the plasma 
membrane upon activation; translocation would bring the enzyme closer to its 
substrate, producing S1P (Ibrahim et al., 2004; Orr Gandy and Obeid, 2013; 
Pitson et al., 2003). Commercial inhibitors of ERK1/2 block the translocation 
and phosphorylation of SphK1 implying the upstream role of ERK1/2 in 
activating of SphK1 (Pitson et al., 2003). ERK1/2 and cyclin-dependent kinase 
2 (CDK2) are shown to phosphorylate SphK1 specifically at Ser225 and 
induce the SphK activity in the cells (Pitson et al., 2003). However, ERK1/2 
can be an upstream or downstream molecule of SphK in the TNF-α signalling 
cascade because phosphorylation of ERK1/2 is also inhibited upon activation 
of TNF-α in dominant-negative SphK cells (Pitson et al., 2003; Pitson et al., 
2000). A site-directed mutagenesis of Gly
82
 to Asp was introduced in the 
catalytic domain of the human SphK to generate the dominant-negative SphK 
mutant, which blocks SphK activation in the cells (Pitson et al., 2000).   
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The second isoform of SphK, SphK2, is expressed mainly in kidney, 
liver and brain (Liu et al., 2000). SphK2 localizes in endoplasmic reticulum 
(ER), nucleus and mitochondria, which is different from the SphK1 
localization; and it is phosphorylated by ERK2 (Orr Gandy and Obeid, 2013). 
SphK2 has a broader range of substrate because it does not only phosphorylate 
D-erythro-sphingosine and D-erythro-dihydrosphingosine, but it also catalyses 
phosphorylation of phytosphingosine, ω-biotinyl D-erythro-sphingosine and 
the SphK inhibitors, FTY720 and D, L-threo-dihydrosphingosine (DHS) 
(Pitman and Pitson, 2010). SphK2 induces apoptosis through its catalytic 
domain, and this is shown to be a calcium dependent process (Maceyka et al., 
2005). The sub-cellular localization and partly the generation of S1P are 
speculated to play a part in the apoptosis induction and the increase of the 
ceramide concentration in the cell (Maceyka et al., 2005). Serum starvation 
affects SphK2 localization in the cells so that it is reduced in the cytosol and 
plasma membrane but relatively increased in the internal membrane (Maceyka 
et al., 2005). 
SphK induces expression of the adhesion molecules VCAM-1 and E-
selectin through activation of NF-κB upon TNF-α activation in human 
umbilical vein endothelial cells (HUVEC) (Xia et al., 1998). Activation of 
SphK increases the level of S1P in the cells, which in turn activates ERK1/2 
phosphorylation but not JNK, and prevents apoptosis (Xia et al., 1998; Xia et 
al., 1999). Activation of SphK and production of S1P are shown to activate 
NF-κB and stimulate the expression of adhesion molecules through S1P (Xia 
et al., 1998). N, N-dimethylsphingosine (DMS) sensitizes HUVEC to 
apoptosis but this is rescued by exogenous S1P (Xia et al., 1999). Physical 
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interaction of TNF receptor-associated factor-2 (TRAF2) with SphK is shown 
to be critical for SphK activation, the anti-apoptotic properties of TRAF-2, and 
also for the activation of the transcription factor NF-κB, but not JNK, in TNF-
α activated HEK293T cells though JNK is often activated in TRAF2-mediated 
signalling pathway (Xia et al., 2002).  
SphK is also shown to be activated in neutrophils and macrophages, 
stimulated by C5a (Ibrahim et al., 2004; Melendez and Ibrahim, 2004). An 
antisense oligonucleotide against SphK1 abolished SphK activity and the 
generation of S1P in human monocyte-derived macrophages (Melendez and 
Ibrahim, 2004). DMS and oligonucleotide against SphK1 also show inhibition 
of the release of Ca
2+
 from internal stores, degranulation, activation of 
nicotimamide adenine dinucleotide phosphate (reduced form) (NADPH) 
oxidase, chemotaxis and cytokines production (TNF-α, IL-6 and IL-8) induced 
by C5a. Increased production of inositol 1, 4, 5-triphosphate (IP3), a sign of 
activation of phospholipase C (PLC), and activation of PKC were observed in 
C5a-stimulated neutrophils but their activities are not regulated by SphK 
(Ibrahim et al., 2004).   
S1P is generated through phosphorylation of sphingosine by SphK in 
the cells. S1P is readily available in platelets at high concentration (Gangoiti et 
al., 2010). S1P, acting as a second messenger, induces cell proliferation and 
promotes cell survival, at the same time it inhibits apoptosis in the cells 
(Spiegel, 1999). S1P production is induced by many stimuli (PDGF, NGF or 
fetal calf serum (FCS) or cross-linking of Fc receptors) (Spiegel, 1999). It can 
also be exported out from the cells through the ATP Binding Cassette (ABC) 
family transporters and spinster 2 (spns2) transporters whereby it will bind to 
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S1P receptors (S1PRs), S1P1R – S1P5R (Orr Gandy and Obeid, 2013). S1P is 
known to act in a paracrine or autocrine manner (Orr Gandy and Obeid, 2013). 
Microinjection of S1P into cells induces a rapid increase of Ca
2+
 which is 
independent of Ca
2+
 influx (Olivera and Spiegel, 2001b). S1P can be 
dephosphorylated to yield sphingosine or degraded by sphingosine phosphate 
lyase (Olivera and Spiegel, 2001b).  
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1.2.3 Sphingosine Kinase Inhibitors 
N, N-dimethylsphingosine (DMS), a competitive inhibitor to SphK, is 
demonstrated to be a more effective SphK inhibitor as compared to DL-threo-
dihydrosphingosine (DHS) (Edsall et al., 1998) and N, N, N-
trimethylsphingosine (TMS) (Igarashi, 1997). SphK activity is halved by low 
concentration of DMS (5µM) and completely abolished at 20µM to 25µM of 
DMS (Edsall et al., 1998). DMS decreases the formation of S1P, and induces 
accumulation of ceramide. In summary, DMS drives the cells to apoptosis 
(Edsall et al., 1998). DMS does not inhibit PKC activity at low concentration 
(10µM) nor does it inhibit the translocation of the PKCα and PKCδ at high 
concentration (50µM) (Edsall et al., 1998).   
D, L-threo-dihydrosphingosine (D, L-threo-DHS or safingol) is capable 
of inhibiting the kinase activity as effectively as the DMS at 5µM. However, 
at higher concentrations, L-threo-DHS may be phosphorylated by SphK and 
generate dihydrosphingosine 1-phosphate because it is a substrate for SphK2 
(Edsall et al., 1998; Pitman and Pitson, 2010). Some effects of the L-threo-
DHS drug enantiomer is reported as an effect from PKC inhibition and in a 
prostate adenocarcinoma study, mice showed symptoms of hepatic toxicity 
after administration of the drug but which was not observed in human patients 
(Pitman and Pitson, 2010). 
N, N, N-trimethylsphingosine (TMS) is generated to replace DMS with 
enhanced water solubility and reduced cytotoxicity. However, this 
replacement is shown to be a less potent SphK inhibitor and its role as anti-
tumour drug was shown through the inhibited PKC activity and not SphK 
(Pitman and Pitson, 2010). 
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Compound 5c (5c) is synthesized as a sphingosine analogue, 
competing for SphK1 with a lower IC50 (3.3µM) relative to DMS 
(IC50=5.7µM) (Wong et al., 2009). 5c is less toxic to U-937 and HL-60 as 
compared to DMS. 5c only starts to show PKC activity inhibition at 100µM 
(Wong et al., 2009). In cancer research, 10µM 5C inhibits SphK activity in 
colorectal cell lines (HCT116, RKO, SW480, SW620) upon cell activation by 
10% fetal bovine serum (FBS) (Tan S, 2011). In HCT-116 cells, 5c inhibits 
translocation of SphK1 from cytosol to plasma membrane and induces 
apoptosis in HCT-116 cells. The combination of 5c and 5-Fluorouracil (5-FU) 
increases the percentage of colorectal cancer cell death, thus, suggesting that 
5c increases the sensitivity of cancer cell to 5-FU treatment (Tan S, 2011). 5-
FU is a chemotherapy agent that has been used to treat colorectal cancer.  
SK1-I (BML-258) is a sphingosine analogue generated by Spiegel and 
co-worker (2008), targeting specifically SphK1. SK1-I is a water soluble 
compound that does not inhibit other kinases such as PKC, SphK2, PKA, 
ERK2 or ceramide kinase (Paugh et al., 2008). It potently inhibits SphK1, 
reduces S1P production, and increases ceramide levels in the cells, hence 
directing the cells towards apoptosis (Paugh et al., 2008). This compound 
inhibits cell proliferation in leukaemia cell lines and is capable of reducing the 
AML xenograft tumour growth (Paugh et al., 2008).  
SKIs (I-IV) are non-lipid SphK inhibitors, identified through screening 
of synthetic compounds using purified human SphK (French et al., 2003). 
SKIs are shown to induce apoptosis in the tumour cells overexpressing the 
drug transport proteins P-glycoprotein or MRP1 (French et al., 2003) . SKI-II 
turns out to be the most selective SphK inhibitor and is an attractive 
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compound because SKI-II is also orally bioavailable (French et al., 2006). 
SKI-I, -II and -V showed inhibition of tumour growth higher than 50% in the 
syngeneic BALB/C mouse solid tumour model that uses JC mammary 
adenocarcinoma (French et al., 2006). SKI shows potential in reducing airway 
inflammation in a murine asthmatic model and acute lung injury after trauma 
and haemorrhagic shock (Gangoiti et al., 2010).  
FTY720 is currently in a clinical trial under its trade name Gilenya
TM 
to treat MS (Orr Gandy and Obeid, 2013). Gilenya (also known as Fingolimod) 
is now approved for the treatment of MS as it reduces relapse rates in the 
patients more efficiently than another drug, interferon (Loma and Heyman, 
2011). FTY720 is a substrate of SphK2 that upon phosphorylation is exported 
out of the cells and binds to the S1PR. FTY720 is also a competitive inhibitor 
of SphK1 that leads to the proteosomal degradation of SphK1a (Orr Gandy 
and Obeid, 2013).  
ABC294640 is a water soluble SphK2 specific enzyme inhibitor, 
possesses a good oral bioavailability with moderate toxicity (Gangoiti et al., 
2010). Its half-time plasma clearance is about 4.5 hours in mice (French et al., 
2010). ABC294640 is a competitive inhibitor that acts as an antitumor agent 
since it induces cell death through autophagy in cancer cells, and inhibits 
metastasis of tumour cells (French et al., 2010; Orr Gandy and Obeid, 2013). 
It also reduces the severity of inflammation in colitis-driven colon cancer and 
in arthritis (Fitzpatrick et al., 2011; Maines et al., 2008). ABC294640 is also 
shown to be gentle to the stomach of the rat model of arthritis as compared to 
non-selective non-steroidal anti-inflammatory drugs (NSAIDs) (Fitzpatrick et 
al., 2011).  
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(S)-FTY720-vinylphosphonate ((S)-vinyl-Pn) inhibits SphK1 in a non-
competitive manner. It leads to the degradation of SphK1, and also acts as 
antagonists to all the S1PRs (Orr Gandy and Obeid, 2013). SG14 or [N-((2S, 
3R)-3-hydroxy-4-phenyl-1-(pyrrolidin-1-yl) butan-2-yl)stearamide)] inhibits 
SphK2 without affecting SphK1 or PKC at a high dose (50µM) while (R)-
FTY720 methyl ether ((R)-FTY720-Ome) induces degradation of SphK2 
through ubiquitin-proteosomal degradation (Orr Gandy and Obeid, 2013; 
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1.2.4 Natural Products As Sphingosine Kinase Inhibitors 
F-12509a is a fungal metabolite that competes for SphK without 
discriminating any isoforms. However, methylation of this hydrophobic 
compound takes away its capability as SphK inhibitor (Pitman and Pitson, 
2010). It blocks production of S1P and causes accumulation of ceramide that 
leads to apoptosis in HL-60 cells (Gangoiti et al., 2010).  
B-5354a, b, c, is isolated from novel marine bacterium SANK71896. 
B-5354c is a non-specific non-competitive inhibitor of SphK in human 
platelets; it inhibits SphK1 activity in a prostate cancer cell line when used 
singly or combined with camptothecin, a potent antitumor agent that targets 
topoisomerase I (Gangoiti et al., 2010). B-5354c does not inhibit other kinases 
such as PKC, PI3-K and ceramide kinase (Pitman and Pitson, 2010). It also 
sensitizes prostate cancer cells to be more responsive to chemotherapy drugs 
such as doxetaxel and camptothecin (Pitman and Pitson, 2010).  
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1.2.5 Sphingosine Kinase In Inflammation 
Sphingosine kinase has been implicated in numerous inflammatory 
diseases such as RA, kidney IRI, airway inflammation, and sepsis (Pitman and 
Pitson, 2010).  
COX-2 is an inflammation mediator that is only expressed upon 
stimulation by inflammatory stimuli such as TNF-α (Pettus et al., 2003). 
Sphingolipid metabolites such as ceramide, sphingosine and S1P increased 
protein levels of COX-2 and production of PGE2 when these metabolites were 
added separately into the fibroblast cells (L929 cell line) (Pettus et al., 2003). 
Inhibition of SphK1, not SphK2, by small interfering ribonucleic acids 
(siRNAs) abolished S1P production, COX-2 activation and prostaglandin E2 
(PGE2) generation in the fibroblast cells (Pettus et al., 2003). 
In the lung injury inflammation model induced by LPS injection, 
SphK1 is shown to play an anti-inflammatory role to dampen the 
inflammation caused by the injury by inhibiting the activation of JNK and 
NADPH oxidase activation (Di et al., 2010). In SphK
-/-
 mice, it was shown 
that there were high levels of cytokines and chemokines in the lungs, namely 
IL-6, MIP-1α, MIP-2 and TNF-α. Neutrophils isolated from SphK-/- mice had 
increased activation of NF-κB by TNF-α stimulation. Increased levels of 
ICAM-1 in endothelial cells induced higher neutrophil infiltration into the 
lungs and this induced higher levels of ROS in the SphK
-/-
 mice as compared 
to the WT mice. Mice with SphK1 knocked out have a lower survival rate and 
a high lung vascular permeability (Di et al., 2010).   
In a murine model of allergic asthma, SphK1 is involved in the 
development of the disease, and inhibiting SphK signalling suppresses the 
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development and severity of the disease (Lai et al., 2008a). DMS and siRNA 
against SphK1 greatly reduce infiltration of inflammatory cells into the lung 
and production of Th2 cytokines (IL-4, IL-5, eotaxin) in the bronchoalveolar 
lavage (BAL) (Lai et al., 2008a). Mucus production and goblet hyperplasia 
were also reduced in the mice treated with higher concentration of DMS in the 
study (Lai et al., 2008a). 
In RA patients, S1P levels are also shown to be higher in the synovial 
fluid as compared to synovial fluid of osteoarthritis patients (Lai et al., 2008b). 
In the murine collagen-induced arthritis (CIA) model, inhibiting SphK1 by 
DMS or siRNA decreases the severity of the disease (Lai et al., 2008b; Lai et 
al., 2009). However, inhibiting the Sphk2 isoform showed a totally opposite 
trend since the inhibition induced a more severe disease development (Lai et 
al., 2009). Treatment with SphK1 siRNA has markedly reduced the level of 
S1P released, decreased the amount of inflammatory cytokines such as TNF-α, 
IL-6 and IFN-γ, which in turn reduced the disease development and severity 
(Lai et al., 2008b; Lai et al., 2009). In the human TNF-α-induced chronic 
inflammatory arthritis mice model, the SphK1 isoform is shown to play a role 
in the inflammatory arthritis too (Baker et al., 2010). SphK
-/-
 mice showed 
significantly lower synovial and periarticular inflammation, less paw swelling 
and deformity and reduced bone erosions; these mice had less articular COX-2 
protein and synovial Th17 cells as compared to SphK
+/+
 mice (Baker et al., 
2010). However, in SphK1
-/- 
mice, CIA and peritonitis are not impaired, and 
no compensatory role is reported for SphK2. This leads to the conclusion that 
the role of SphK1 in inflammation is dispensable (Michaud et al., 2006). 
Another group reported that the SphK2 specific inhibitor, ABC294640, also 
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slowed down the disease progression in the same murine CIA model 
(Fitzpatrick et al., 2011). In the rat adjuvant-induced arthritis (AIA) model, 
ABC294640 significantly reduced the severity of the disease as seen in the 
reduction of joint inflammation, synovial hyperplasia, pannus formation, 
cartilage destruction and bone deformation in the tibiotarsal joints of the rats 
(Fitzpatrick et al., 2011). Baker et al. (2012) reported otherwise in the TNF-α-
induced arthritis using the same SphK2 inhibitor, ABC294640 (Baker et al., 
2012). Treating the arthritic mice with ABC294640 had worsen the arthritis 
condition in the mice while the SphK2
-/-
 mice did not show any difference in 
the disease progression (Baker et al., 2012). The group suggested that the 
difference between acute inhibition by ABC294640 and lifelong SphK2 
deficiency may contribute to the different outcome of the disease progression 
in arthritis, apart from the drug dosage used in the experiment (Baker et al., 
2012).  
In the murine renal IRI model, A1 adenosine receptor (A1AR) 
activation induces SphK activity in the kidney which leads to the production 
of S1P (Park et al., 2012). The activation of A1AR upregulates SphK1 protein, 
but not SphK2 protein. SphK1
-/-
 mice have increased renal injury through 
necrosis and inflammation. Plasma creatinine levels are also higher in SphK1
-/-
 
mice (Park et al., 2012). SphK1 seems to play a role in protecting the mice 
from severe renal injury as neutrophil infiltration in the kidneys, ICAM-1 and 
TNF-α mRNA expression are lower in WT mice as compared to SphK1-/- mice 
(Park et al., 2012). The high production of S1P and the exporting of S1P from 
the cells, leading to the binding to the S1P1R protect the cells from 
inflammation and necrosis (Park et al., 2012). 
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In the murine chronic and acute dextran sulphate sodium (DSS)-
induced ulcerative colitis model, SphK inhibition by ABC294640 and 
ABC747080 reduce the infiltration of neutrophils to the site of inflammation, 
and the production of inflammatory cytokines such as TNFα, IL-1β, IL-6, 
IFN-γ and S1P (Maines et al., 2008). PGE2 production and also the expression 
of adhesion molecules, ICAM-1 and VCAM-1, are markedly decreased 
(Maines et al., 2008). The effectiveness of ABC294640 and ABC747080 is 
comparable to that of Dipentum (olsolazine), a FDA-approved anti-colitis drug 
(Maines et al., 2008). ABC294640 and ABC747080 reduce disease 
progression and colon shortening (Maines et al., 2008). 
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1.3 Phospholipase D, Protein Kinase C And Sphingosine Kinase 
Phospholipase D (PLD) is an important phospholipid enzyme that 
catalyses phosphotidylcholine to produce phosphatidic acid (PA) and choline. 
TNF-α activates PLD as early as 2 minutes in monocytes and mobilizes PLD1 
from the cytosol to the membrane (Sethu et al., 2008). PLD1 is also shown to 
induce activation of SphK and the release of cytosolic Ca
2+
 upon stimulation 
of monocytes with TNF-α. An antisense oligonucleotide against PLD1 inhibits 
activation of ERK1/2 and NF-κB and the secretion of cytokines such as IL-1β, 
IL-5, IL-6 and IL-13 (Sethu et al., 2008). In FcγR1-stimulated monocytes, 
PLD is activated and induces activation of SphK and calcium transients 
(Melendez et al., 2001). The signalling pathway downstream of FcγR1 in 
monocytes, through PLD leads to the activation of NADPH oxidase burst 
(Melendez et al., 2001). 
PKC is shown to mediate the translocation of SphK1 to the plasma 
membrane because treatment with the PKC inhibitors, Bisindolylmaleimide 
and Calphostin-c, abolishes the translocation of the enzyme after stimulation 
by phorbol 12-myristate 13-acetate (PMA) (Johnson et al., 2002). PMA, a 
PKC activator, also induces the phosphorylation and activity of SphK1, 
followed by S1P production (Johnson et al., 2002). A dominant negative 
G82D mutation also translocates to the membrane upon stimulation with PMA, 
indicating that activity of the kinase is not required for the translocation in 
HEK293 cells (Johnson et al., 2002).  
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1.4 Monocytes/Macrophages And Chemokines 
There are about 5-10% of mature monocytes among the circulating 
peripheral blood leukocytes. Monocytes, originating from the bone marrow, 
give rise to specialized cells such as DC or macrophages or osteoclasts under 
the different microenvironments they migrated to (Gordon and Taylor, 2005). 
Heterogeneity is common in the monocyte pool due to the different expression 
of surface markers on the monocytes such as CD14, CD16, CD32, CD64 and 
many more (Gordon and Taylor, 2005). Monocytes, may differentiate into 
macrophages or DC, are part of the first line defence of the immune system, 
and they are critical in eradicating pathogens from the body (Gordon and 
Taylor, 2005). Human monocytes differentiate into DC in the presence of 
GM-CSF and IL-4, and DC differentiation is said to favour monocytes with 
high expression of CD14 and CD16 (Gordon and Taylor, 2005). Differential 
expression of antigenic markers generates a heterogeneous pool of monocytes 
(Gordon and Taylor, 2005). There are two main subsets of monocytes mainly 













 cells are generally called the classical monocytes, mainly 




 monocytes are 
non-classical monocytes, expressing CCR5 (Gordon and Taylor, 2005). 
Classical monocytes are said to be the first to be recruited to the inflammation 
sites after neutrophils, and this extravasation is highly dependent on 
chemokine receptors, e.g. CCR2 (Ingersoll et al., 2011). Monocyte 
mobilization from bone marrow to the inflamed tissues during bacterial 
infection is shown to rely on the expression of the CCR2 on monocytes. 
Lacking of CCR2 expression on monocytes traps the cells in the bone marrow, 
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unable to leave for the infection sites (Serbina and Pamer, 2006). Non-
classical monocytes are recruited to the inflammation site for tissue healing, 
and the CX3CR1 receptor is found to be the one responsible for such migration 
(Ingersoll et al., 2011). Macrophages are important for maintaining 
homeostasis, clearance of dead cells, remodelling and repair of tissues 
(Gordon and Taylor, 2005). They specialize in tissues they are residing in, 
such as the osteoclasts for bone remodelling, alveolar macrophages in lungs to 
clear the microorganisms and contaminants from environment, microglia in 
the central nervous system or Kupffer cells in the liver (Gordon and Taylor, 
2005).  
During inflammation or infection, leukocytes are recruited to the 
inflamed tissues, guided by the chemokine gradients. Leukocytes move 
towards high chemokine concentrations (Deshmane et al., 2009). Certain 
chemokines are normally elevated at the site of inflammation to selectively 
attract the appropriate types of cells which express the matching chemokine 
receptors. This is viewed as a way to recruit the immune cells to the 
inflammation site as a host defence mechanism against infection (Deshmane et 
al., 2009). Initial migration of monocytes to the inflamed peritoneum is found 
to be highly dependent on the expression of CCR2 on the monocytes (Tsou et 
al., 2007).  
Progression of an inflammation or infection depends on the extent of 
the recruitment of immune cells to the infected sites, and how the 
inflammation is regulated (Power and Proudfoot, 2001). Leukocyte homing 
relies on the signals generated by the inflamed cells, through generation of 
chemokines and adhesion molecules (Power and Proudfoot, 2001). Lowering 
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or inhibiting the level of chemokines is proven to decrease the level of 
inflammation because this prevents excessive numbers of leukocyte 
infiltrating into the inflamed tissues (Power and Proudfoot, 2001).  
Chemokines are divided into four subfamilies: (X) C, CC, CXC and 
CX3C and are subdivided into two main functions i.e. inflammatory and 
homeostatic chemokines (Deshmane et al., 2009; Zlotnik and Yoshie, 2012). 
In many cases, multiple chemokines are secreted within the inflammation site 
for recruitment of leukocytes, making the process of leukocyte mobilization 
seem complicated and complex (Table 1) (Rottman, 1999; Zlotnik and Yoshie, 
2012). Another possible hypothesis is that only one particular chemokine is 
responsible for leukocyte homing through its chemokine gradient, after which 
leukocytes become desensitized and move on to another chemokine gradient 
until they reached the destination (Rottman, 1999). Chemokines are effective 
in leukocyte homing, and it has been established that lymphocyte maturation 
too may involve chemokine expression at different lymphoid tissues (Rottman, 
1999). Th1 and Th2 are two different lymphocyte subsets which are 
characterised by expressing different sets of chemokine receptors which are 
important for their homing to different inflamed tissues (Rottman, 1999). Th1 
cells mainly express CCR5 and CXCR3, Th2 cells express CCR3 while both 
subsets express CCR2 and CXCR4 (Rottman, 1999).  
CC chemokines such as MCP-1, regulated on activation, normal T cell 
expressed and secreted (RANTES), and MIP-1β are chemotactic for cells of 
the monocyte lineage and lymphocytes, with the majority encoded on 
chromosome 17 in humans (Cook, 1996; Deshmane et al., 2009). CXC 
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chemokines such as IL-8 are chemo-attractants for neutrophils, and are located 
on chromosome 4 in man (Cook, 1996; Deshmane et al., 2009).  
MCP-1 (also known as CCL2), which binds to CCR2, was first 
identified as a chemotactic factor of monocytes. It is also found to mobilize 
memory T lymphocytes and NK cells. MCP-1 is found in MS, RA, psoriasis, 
atherosclerosis and diabetes (Deshmane et al., 2009). CCR2 is shared by a few 
ligands (e.g. CCL2, CCL7, CCL8, CCL16) and its expression is restricted to 
specific types of cells such as mononuclear cells, vascular smooth muscle cells, 
monocytes and NK cells (Deshmane et al., 2009; Zlotnik and Yoshie, 2012). 
CCR2 is postulated to be inflammatory or anti-inflammatory in its effects, 
depending on the type of cells it is expressed on. For instance, CCR2 on APCs 
and T cells acts inflammatory, and CCR2 on regulatory T cells acts anti-
inflammatory (Deshmane et al., 2009). 
MIP-1α and MIP-1β induce mobilization of monocytes and T cells 
with different resulting activities (Cook, 1996). MIP-1α mainly induces the 
chemotaxis of B lymphocytes, activated CD8
+
 T lymphocytes, NK cells and 
eosinophils. Further, MIP-1α stimulates ICAM-1 expression, mast cell 
degranulation, histamine release by basophils and the production of other 
inflammatory cytokines (Cook, 1996). Coxsackievirus B3 (CVB3)-induced 
myocarditis does not developed in MIP-1α-/- mice, proving that MIP-1α is an 
essential chemokine in developing myocarditis in mice (Cook, 1996). MIP-1α 




 mice, monocytes are retained in the bone marrow despite 
monocytosis which is induced by hypercholesterolemia. The population of 
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monocytes residing in the bone marrow increases with the decrease in number 
of monocytes in the circulation (Tsou et al., 2007). MCP-1, MCP-3 and their 





 mice show fewer monocytes circulating in the 






 mice have normal 
monocyte counts in the blood (Tsou et al., 2007). However, CCR2 expression 
on monocytes is found to be the most critical factor in the migration of 
monocytes out of the bone marrow (Tsou et al., 2007). 
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XCL2 SCM-1β XCR1  
CC Subfamily 
CCL1 I-309 CCR8  
CCL2 MCP-1 CCR2  
CCL3 MIP-1α, LD78α CCR1, CCR5  
CCL3L1 LD78β CCR1, CCR3, 
CCR5 
 
CCL3L3 LD78β   
CCL4 MIP-1β CCR5  
CCL4L1 AT744.2   
CCL4L2 -   
CCL5 RANTES CCR1, CCR3, 
CCR5 
 
CCL7 MCP-3 CCR1, CCR2, 
CCR3, CCR5 
CCR5 
CCL8 MCP-2 CCR1, CCR2, 
CCR5 
 
CCL11 Eotaxin CCR3, CCR5 CXCR3, CCR2 
CCL13 MCP-4 CCR2, CCR3  
CCL17 TARC CCR4  
CCL20 MIP-3α, LARC CCR6  
CCL22 MDC CCR4  
CCL26 Eotaxin-3 CCR3, CXCR1 CCR1, CCR2, 
CCR5 
CXC Chemokine  
CXCL1 GROα, MGSA CXCR2  
CXCL2 GROβ CXCR2  
CXCL3 GROγ CXCR2  
CXCL5 ENA78 CXCR2  
CXCL6 GCP2 CXCR1, CXCR2  
CXCL7 NAP-2 CXCR1, CXCR2  
CXCL8 IL-8 CXCR1, CXCR2  
CXCL9 MIG CXCR3 CCR3 
CXCL10 IP-10 CXCR3 CCR3 
CXCL11 I-TAC CXCR3, CXCR7 CCR3, CCR5 
CXCL16 SR-PSOX CXCR6  
CX3C chemokine 
CX3CL1 Fractalkine CX3CR1  
Table 1 Inflammatory Chemokines. Modified from (Zlotnik and Yoshie, 2012).  
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1.4.1 Chemokines In Diseases 
In many inflammatory diseases, such as MS, asthma or psoriasis, 
chemokines and/or their receptors are present at the inflammatory sites 
(Rottman, 1999). In RA patients, synovial tissues form the patients contain 
chemokines MCP-1, MIP-1α, IL-8 and RANTES, and the chemokine 
receptors CXCR3 and CCR5 are expressed on the lymphocytes that migrated 
to these tissues (Rottman, 1999). Chemokines binding to CCR1 may be the 
first of few that are secreted to initiate inflammatory responses because CCR1
-
/-
 mice were spared from pulmonary granuloma formation and were protected 
from pulmonary inflammation when Schistosoma mansoni eggs were injected 
intravenously (Rottman, 1999).  
In kidney IRI model, monocytes infiltrate into the kidney through the 
binding of chemokine receptors on the monocytes to the chemokines 
generated at the injured kidney (Li et al., 2008). CCR2 and CXCR1 are 





 mice have lower numbers of macrophages compared to control 
mice (Li et al., 2008). Tubule necrosis is also reduced in CCR2
-/-
 and CX3CR1 
deficient mice (Li et al., 2008). 
In a murine model of endotoxemia or in acute lung injury induced by 
LPS, 20 inflammatory mediators were analysed closely using multiplex bead-
based assay including the chemokines (Bosmann et al., 2012). In endotoxemia, 
endotoxic shock, which is done by administrating LPS into the peritoneum, 
most of the mediators were upregulated substantially by the third hour after 
administration of LPS including chemokines such as eotaxin, keratinocyte 
chemoattractant (KC), MCP-1, MIP-1α, MIP-1β and RANTES (Bosmann et 
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al., 2012). Some of the mediators were sustained at high levels for up to 12 
hours after induction (Bosmann et al., 2012). These six chemokines (eotaxin, 
KC, MCP-1, MIP-1α, MIP-1β and RANTES) were also found to be 
upregulated in LPS-induced lung injury from 4
th
 hour to 18
th
  hour after 
induction (Bosmann et al., 2012).  
MCP-1, but not MCP-2, MCP-3 or MCP-5, is proven to play a crucial 
role in the development of EAE. MCP-1
-/-
 mice are resistant to the disease, 
and have substantially reduced numbers of macrophages infiltrating into the 
CNS (Huang et al., 2001). Other inflammatory cytokines such as MIP-1α, 
IFN-γ-inducible 10 kDa Protein (IP-10), RANTES and IFN-γ are significantly 
reduced in the MCP-1
-/-
 mice upon EAE onset in the spinal cord (Huang et al., 
2001). There were no compensatory roles played by MCP-2, MCP-3 or MCP-
5 in the MCP-1
-/-
 mice (Huang et al., 2001). 
In another report, there were increased chemokine levels such as IP-10, 
monokine induced by IFN-γ (Mig) and RANTES in the cerebrospinal fluid in 
MS patients (Sørensen et al., 1999). Not only the chemokine levels were 
elevated, the corresponding receptors of the chemokine expressions were also 
enhanced such as CXCR3 (IP-10/Mig Receptor) on the lymphocytic cells, 
CCR5 (RANTES receptor) on lymphocytic cells, macrophages, and microglia 
in the actively demyelinating MS brain lesions (Sørensen et al., 1999). 
In Zymosan-induced inflammation in the peritoneal cavity, a large 
number of leukocytes and monocytes infiltrate into the cavity as the level of 
MCP-1, TNF-α, KC and MIP-1α increased (Ajuebor et al., 1998). The number 
of leukocytes infiltrating the cavity is markedly reduced when anti-mouse 
MCP-1 antibody is injected after the Zymosan administration (Ajuebor et al., 
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1998). MCP-1, when artificially administrated into the cavity, attracts 
leukocytes and monocytes as part of the host defence system (Ajuebor et al., 
1998). However, MIP-1α secretion during the inflammation is affected by 
MCP-1 neutralization (Ajuebor et al., 1998). 
MCP-1 and MCP-3 are crucial in recruiting inflammatory monocytes 
to the infection sites during Listeria monocytogenes infection in mice (Jia et 
al., 2008). Manipulating knockout mice of MCP-1
 
and MCP-3, CCR2-
mediated recruitment of inflammatory monocytes to the infection site was 
much reduced. The inflammatory monocytes accumulated in the bone marrow 
of the mice during infection (Jia et al., 2008). In the absence of MCP-1 or 
MCP-2, mice are more susceptible to infection and take longer time to clear 
the bacteria from the system (Jia et al., 2008).  
Transplant rejection is characterized by production of multiple 
chemokines, and leukocyte infiltration at different stages of the rejection. 
MIP-2, KC, and MCP-1 are involved in the early stage followed by IP-10, 
MIG, IFN-γ-inducible T-cell chemoattractant (ITAC), MIP-1β and RANTES 
at the later stage. Production of these chemokines is responsible for the 
potential rejection of a transplant from the body (Power and Proudfoot, 2001).  
Power and Proudfoot (2001) proposed to treat acute and chronic 
inflammatory diseases by blocking the interaction of the chemokines with 
their receptors (Power and Proudfoot, 2001). Met-RANTES, an antagonist of 
CCR1 and CCR5, and anti-RANTES neutralizing antibodies are shown to be 
effective in reducing leukocyte infiltration and recruitment in the renal 
transplantation and lung allograft rejection respectively (Power and Proudfoot, 
2001).  
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A lot of research involving neutralizing or knocking out chemokine 
receptors was done to investigate the effectiveness of the approach on the 
model of cardiac allograft rejection (Power and Proudfoot, 2001). CCR
-/-
 mice 
showed no signs of rejection of cardiac allografts. The same was achieved 
with treatment by a monoclonal antibody against the MHC class II co-receptor 
CD4 or by deletion of the CCR2 and CCR5 genes (Power and Proudfoot, 
2001). CXCR3 deletion or anti-CXCR3 monoclonal antibodies postponed or 
completely abolish the cardiac allograft rejection (Power and Proudfoot, 
2001). These studies demonstrate the critical and essential role that 
chemokines are playing in the inflammatory diseases and transplant rejection.  
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1.5 Rationale And Aims Of The Project 
CD137 and CD137L are found to play a role in inflammatory diseases 
such as RA, MS, EAE and kidney IRI (Croft et al., 2012). CD137 expression 
is elevated at the site of inflammation, and activation of CD137 on endothelial 
cells increases the expression of adhesion molecules such as ICAM-1, V-
CAM1 which are important for extravasation of monocytes into the inflamed 
tissues.   
Phospholipid modifying enzymes, like SphK and PLD, also regulate 
immune responses in inflammation, including RA, MS, EAE and kidney IRI. 
Inhibiting SphK enzymes suppresses the development of the inflammatory 
disease and dampens the degree of inflammation occurring in the tissues. At 
present, TNF-α has been shown to activate the PLD and/or SphK enzymes in 
monocytes and HUVEC (Sethu et al., 2008; Xia et al., 1998; Xia et al., 1999).  
In TNF-α activated monocytes, PLD1 is shown to induce secretion of 
inflammatory cytokines, phosphorylation of ERK1/2, and also activation of 
NF-κB, and these activities are mediated by SphK1 (Sethu et al., 2008). In 
monocytes, CD137L reverse signalling also activate ERK1/2, and NF-κB 
(Söllner et al., 2007).  
 Would SphK and PLD then be involved in the CD137L reverse 
signalling in monocytes given that CD137 and CD137L belong to the TNF 
receptor and TNF superfamilies, respectively, in the manner as reported by 
Sethu et al. (2008) (Sethu et al., 2008)? Does CD137L reverse signalling 
enhance SphK and PLD activities as the downstream signalling cascade steps, 
or do they work in parallel to elicit robust inflammatory reactions in the 
tissues?         
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In this research project, we are interested to investigate the potential 
involvement of phospholipid signalling in the CD137L reverse signalling 
pathway in leukocytes, particularly in monocytes. We would like to identify 
the phospholipids mediating the signalling pathway activated by CD137L in 
monocytes.  
In many signalling pathways, PKC is always being discussed for it is a 
classic crucial second messenger. Söllner et al. (2007) had reported that PKC 
is not involved in the CD137L reverse signalling pathway in monocytes as the 
inhibitor used, Chelerythrine chloride (up to 3µM), did not affect the 
production of IL-8 (Söllner et al., 2007). We would like to reinvestigate to 
confirm that this important classical second messenger, PKC, is not involved 
in the downstream signalling by CD137L as reported by Söllner et al. (2007) 
(Söllner et al., 2007).  
The importance of chemokines and their receptors in monocyte 
migration to the inflammation site is undeniable as demonstrated by 
chemokine or chemokine receptor knockout mice. Chemokine production at 
the inflammation site is crucial to generate chemokine gradients for 
recruitment of immune cells to the inflamed tissues. Different groups of 
chemokines are responsible for the recruitment of different types of immune 
cells to the site. Hence, we are also interested to understand the type of 
chemokines generated by monocytes in response to CD137L reverse 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Reagents And Chemicals 
- All reagents and chemicals unless stated otherwise, were purchased 
from Sigma-Aldrich. 
- Recombinant human CD137-Fc protein, which is a fusion protein 
consisting of the extracellular domain of human CD137, fused to the 
constant domain (Fc) of human IgG1 was purchased from ALEXIS 
Biochemicals (USA).  
- Human IgG1-Fc protein was purchased from Chemicon International 
(USA). 
- N,N-Dimethylsphingosine (DMS) was purchased from Calbiochem 
(USA) 
- Compound 5c (5c) was generated by Wong et al. (2009) (Wong et al., 
2009) 
- Butan-1-ol and tertiary butanol (t-butanol) were purchased from 
MERCK (USA) 
- Bisindolylmaleimide I (Bis I) was purchased from Cell Signaling 
Technology, Inc., USA 
- Dimethylformamide (DMF) was purchased from Merck, USA. 
 
2.2 Solutions And Buffers 
- RIPA buffer for total cell lysate preparation: 50mM Tris-HCl (pH 7.4), 
1.0% NP-40, 0.25% sodium deoxycholate, 150mM sodium chloride, 
1.0mM Ethylenediaminetetraacetic acid (EDTA). 
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- Protease inhibitors cocktail for RIPA buffer: 1X complete, EDTA-free 
Protease Inhibitor Cocktail Tablets (Roche, USA).  
- Phosphatase inhibitors cocktail for RIPA buffer: 1X phosSTOP (Roche, 
USA) 
- Resolving gel for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE): Distilled water, 30% Bis-acrylamide 
(Bio-Rad Laboratories, USA), 1.5M Tris (pH 8.8), 10% SDS, 10% 
ammonium persulfate (APS), Tetramethylethylenediamine (TEMED) 
(Bio-Rad Laboratories, USA). 
- Stacking gel for SDS-PAGE: Distilled water, 30% Bis-acrylamide 
(Bio-Rad Laboratories, USA), 1.0M Tris (pH 6.8), 10% SDS, 10% 
APS, TEMED (Bio-Rad Laboratories, USA) 
- Running buffer for SDS-PAGE: 25mM Tris base, 250mM glycine, 0.1% 
SDS, pH 8.3. 
- Transfer buffer for SDS-PAGE: 25mM Tris base, 250mM glycine, 
0.025% SDS, pH 8.3. 
- 1X SDS gel-loading buffer for SDS-PAGE: 50mM Tris HCl (pH 6.8), 
100mM β-mercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% 
glycerol. 
- Washing buffer for SDS-PAGE: 1X Tris-buffered saline (TBS), 0.1% 
Tween 20 (Bio-Rad Laboratories, USA). 
- Diluent buffer for ELISA: 10% bovine serum (Gibco, New Zealand). 
- Washing buffer for ELISA: 1X Phosphate-buffered saline (PBS), 0.05% 
Tween 20 (Bio-Rad Laboratories, USA).  
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- SphK buffer for measurement of SphK activity: 50mM 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid (pH 7.4), 15mM 
magnesium chloride (MgCl2), 0.005% Triton X-100, 10mM potassium 
chloride (KCl). 
 
2.3 Cell Line 
The THP-1 and U-937 cell lines were obtained from American Type 
Culture Collection (ATCC). Cells were cultured in polystyrene flasks (NUNC, 
USA) in Roswell Park Memorial Institute (RPMI) 1640 (Sigma Aldrich, USA) 
supplemented with 10% heat deactivated FBS (Gibco, USA) at 37°C and 5% 
carbon dioxide in water saturated atmosphere.  
 
2.4 Stimulation Of Cells 
2.4.1 Protein Immobilization  
Plates were coated overnight at 4°C with either 5µg/ml of human CD137-Fc 
or human IgG1-Fc (negative control) for stimulation of cells. Table 2 shows 
the volume of CD137-Fc used to coat the different sizes of plates. Plates were 
washed once with sterile 1X PBS before seeding cells onto the plate for 
stimulation. 
 
Plates Volume used per well (µl) 
96-well plate 50 
48-well plate 130 
24-well plate 250 
12-well plate 500 
6-well plate 750 
Table 2. Volume of protein added into tissue culture plates. 
 
50
CHAPTER 2: MATERIALS AND METHODS 
 
2.4.2 CD137 Ligand Stimulation 
Prior to experiments, cells (1.0 million/ml) were cultured in RPMI 1640 
supplemented with 1% FBS for 18 hours. The cells were incubated with the Fc 
receptor blocking antibody (Miltenyi, Germany) according to the 
manufacturer’s recommendations, at 4°C for 45 minutes. Cells were then 
washed twice with ice cold 1X PBS, and resuspended in RPMI 1640 with 10% 
FBS at a density of 0.5million/ml for stimulation at 37°C. Table 3 shows the 
amount of cells used in different size of plates. CD137-Fc coated and human 
IgG-Fc coated plates were washed once with 1X PBS before cells were added. 
Upon the addition of cells into respective wells, the plates were kept in the 
37°C incubator to start the reaction. Reactions were stopped with 1.0ml of ice 
cold 1X PBS at various time points and cell pellets were collected for 
subsequent experiments. 
 
















Table 3. Amount of THP-1 cells added into tissue culture plates. 
 
2.5 Preparation And Treatment Of Inhibitors 
2.5.1 Preparation Of DMS And Compound 5c 
DMS was prepared as a 10mM stock in 100% dimethyl sulfoxide (DMSO). A 
final concentration of 10µM DMS was used in all experimental set-ups. 
DMSO was kept at 0.1% (v/v) concentration in all experimental set-ups.  
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Compound 5c was prepared as 50mM and 25mM stock respectively in 100% 
DMSO. A final concentration of 50µM and 25µM 5c were used respectively 
in all experimental set-ups. DMSO was kept at 0.1% (v/v) concentration in all 
experimental set-ups.  
 
2.5.2 Preparation Of Bisindolylmaleimide I 
Bis I was prepared as a 500µM stock in 100% DMSO. A final concentration 
of 500nM Bis I was used in all experimental set-ups. DMSO was kept at 0.1% 
(v/v) concentration in all experimental set-ups. 
 
2.5.3 Sphingosine Kinase Inhibition  
A final concentration of 10µM of DMS, 50µM and 25µM of 5c were used in 
all experimental set-ups. Inhibitors were added into the cell suspension and 
incubated on ice for 15 minutes. Cells were then transferred into the coated 
plates for stimulation; cells without any addition of inhibitors served as 
controls. 
 
2.5.4 Phospholipase D Inhibition 
A final concentration of 0.3% (v/v) of primary alcohol, butan-1-ol, was used 
in all experimental set-ups. 0.3% (v/v) of t-butanol was used as control of the 
primary alcohol for this inhibition experiment. 0.3% of butan-1-ol or 0.3% of 
t-butanol were added into the cell suspension and incubated on ice for 15 
minutes. Cells were then transferred into the coated plates for stimulation; 
cells without any addition of alcohols served as controls. 
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2.5.5 Protein Kinase C Inhibition 
A final concentration of 500nM of Bis I was used in all experimental set-ups. 
Inhibitor was added into the cell suspension and incubated on ice for 30 
minutes. Cells were then transferred into the coated plates for stimulation; 
cells without any addition of Bis I served as controls. 
 
2.6 Morphological Changes 
THP-1 cells were cultured in the CD137-Fc coated or human IgG-Fc coated 
plates. Uncoated and Fc coated plates served as control in this experimental 
set-up. Morphological changes were captured at 24 hours and 48 hours using 
the Olympus IX81 motorized inverted research microscope (Olympus) and 
DP71 microscope digital camera (Olympus). 
 
2.7 Preparation Of Cell Extracts 
Cell pellets were lysed with RIPA buffer supplemented with protease 
inhibitors and phosphatase inhibitors (Roche, USA). 70µL of RIPA buffer was 
used for every 1x10
6
 THP-1 cells. Cells resuspended in RIPA buffer were 
subjected to vigorous vortexing followed by incubation at 4°C for 45 minutes. 
Cell nuclei and debris were removed by centrifugation at 13000 RPM, 4°C for 
5 minutes. Protein concentrations were determined by the Bradford assay 
using Bio-Rad Protein Assay (Biorad, USA).  
 
2.8 Western Blot 
Equal amount of protein lysates (15µg to 40µg) were prepared in 1X SDS 
Gel-loading buffer; samples were heated at 95°C for 5 minutes, separated on a 
53
CHAPTER 2: MATERIALS AND METHODS 
 
12% SDS PAGE gel under reducing conditions and blotted onto 
Polyvinylidene fluoride (PVDF) (Millipore, USA). Blots were probed with 
primary antibodies at 4°C overnight followed by appropriate secondary 
antibody conjugated to horseradish peroxidase (HRP). Immunocomplexes 
were visualized by enhanced chemiluminescence (ECL) (Thermo Scientific, 
USA) on films. Table 4 shows the list of primary antibodies and their 
corresponding secondary antibodies used.     
 
Primary Antibody Secondary antibody 
Mouse anti-α -tubulin  
(Santa Cruz, Biotechnology Inc., USA) 
Anti-mouse IgG HRP  
(Sigma Aldrich, USA) 
Mouse anti-GAPDH  
(Santa Cruz Biotechnology Inc., USA) 
Anti-mouse IgG HRP  
(Sigma Aldrich, USA) 
Rabbit anti-Sphingosine Kinase 1  
(Cell Signaling Technology Inc., USA) 
Anti-rabbit IgG HRP  
(Thermo Scientific, USA) 
Table 4. List of primary antibodies and corresponding secondary antibodies. 
 
2.9 Measurement Of Sphingosine Kinase Activity Using Fluorometric 
Assay 
This protocol was adapted from Billich and Ettmayer (2004) (Billich 
and Ettmayer, 2004). A total protein of 40μg from cell lysate was used for the 
reaction. The lysate was incubated with 20μM of 15-NBD-Sph (prepared as a 
complex with bovine serum albumin (BSA)) and ATP (1mM) in SphK buffer 
in the final volume of 100μL. After incubation at 37°C in water bath for 30 
minutes, 100μl 1M potassium phosphate buffer, pH 8.5, was added to stop the 
reaction. 500μl chloroform/methanol (2:1) (Merck, USA) were added. The 
mixture was vortexed and the phases were separated by centrifugation at 5000 
RPM for 5 minutes at room temperature. An aliquot of 75μl was removed 
54
CHAPTER 2: MATERIALS AND METHODS 
 
from the upper aqueous layer and transferred into the wells of black 96-well 
polystyrene microplates (Greiner Bio-One, USA), followed by 75μl of 
dimethylformamide (DMF) (Merck, USA). Fluorescence intensity was 
measured with excitation wavelength at 485nm and emission wavelength at 
535 nm. A reaction mixture containing no protein lysate served as blank. 
 
2.10 Preparation Of Supernatants 
Cells were cultured in CD137-Fc-coated 48-well plate at 37°C for 24 
hours. For sphingosine kinase inhibition, cells were cultured with and without 
the presence of DMS, compound 5c and DMSO; for PLD inhibition studies, 
cells were cultured with and without 0.3% of butan-1-ol and 0.3% of t-butanol; 
and for PKC inhibition studies, cells were cultured with and without Bis I and 
DMSO. Both uncoated wells and wells coated with human IgG1-Fc served as 
controls. Cells were spun down at 1000 RPM for 5 minutes and supernatants 
were collected for cytokine analysis. Each sample supernatant collected was 
prepared in triplicates within each experiment.  
 
2.11 Measurement Of Chemokines Using Enzyme-Linked Immunosorbent 
Assay (ELISA) 
The concentration of IL-8 and MCP-1 in cell supernatants was 
determined by the BD OptEIA
TM
 human IL-8 enzyme-linked immunosorbent 
assay (ELISA) Set and BD OptEIA
TM
 MCP-1 ELISA Set. The concentrations 
of MIP-1α and MIP-1β in cell supernatants were determined by the human 
MIP-1α and MIP-1β DuoSet ELISA kits (R&D Systems), respectively. ELISA 
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was performed on Maxisorb plates (NUNC, USA) according to the 
manufacturers’ instructions.  







MIP-1 α (R&D Systems DuoSet ELISA kits) 15.6pg/ml 
MIP-1 β (R&D Systems DuoSet ELISA kits) 7.8pg/ml 
Table 5. List of the lower detection limit of all ELISAs. 
 
2.12 Statistics 
Statistical significance of the differences between the means of two 
groups was determined by the two sided unpaired Students’ t-test. Levels of 
significance were set at p < 0.05 and p < 0.01. 
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It is important to highlight here that the results presented are due to the 
effect of cross-linking of CD137L on THP-1 cells. Immobilized CD137-Fc 
protein was used to induce the CD137L signalling in THP-1 cells in all 
experimental set-ups. CD137-Fc is a recombinant fusion protein consisting of 
the extracellular domain of human CD137 linked to the constant domain of 
human IgG1 (Fc) (Langstein et al., 1998). Recombinant Fc protein and 
uncoated plates were used as negative controls. Plates were coated overnight 
at 4°C with either 5µg/ml of human CD137-Fc or human IgG1-Fc. CD137-Fc 
needed to be immobilized onto plates because it has been shown that soluble 
CD137-Fc is not able to induce CD137L signalling and monocyte activation 
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3.1 CD137L Induced Adherence And Morphological Changes In THP-
1 Cells 
Morphological changes induced by cross-linking of CD137L are a 
characteristic feature of activated monocytic cells as reported by Langstein et 
al. (1998, 1999) and Söllner et al. (2007) (Langstein et al., 1998; Langstein 
and Schwarz, 1999; Söllner et al., 2007). THP-1 cells were cultured in CD137-
Fc coated or Fc coated plates for 24 hours and 48 hours to observe the 
morphological changes. Uncoated plate and Fc coated plates were used as 
controls in this experimental set up. In CD137-Fc coated wells, THP-1 cells 
adhered strongly to the plate by 24 hours and some had changed their 
morphology from round and spheric to elongated and spread-out. Such 
features were not found in the two control wells (Figure 1). By 48 hours, these 
morphological changes in the CD137-Fc coated wells were even more 
profound and distinct. In a separate experiment, THP-1 cells were observed to 
attach to CD137-Fc coated plates as early as 30 minutes. A strong adherence 
was observed after 60 minutes of incubation of THP-1 cells in CD137-Fc 
coated plates. These observations were used in subsequent experiments as 
evidence that cells were indeed activated by CD137L signalling.   
  
58





















Figure 1. CD137 ligand signalling induced THP-1 cells activation. 5x10
4
 
THP-1 cells were incubated in uncoated or CD137-Fc coated or Fc coated 
plates. Cells were viewed under the Olympus IX81 microscope and 
photographed after 24 hours and 48 hours. 
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3.2 Involvement Of Sphingosine Kinases, Not Phospholipase D, In 
CD137L-Activated Cells  
Another key feature of CD137L activation in monocytic cells is the 
production of the pro-inflammatory chemokine, IL-8. High levels of IL-8 
production were reported by Söllner et al. when cells were activated by 
CD137-Fc protein (Söllner et al., 2007). This piece of information has been 
used as a determinant of activation of the monocytic cells by the cross-linking 
of CD137L.   
THP-1 cells were cultured on uncoated or CD137-Fc protein coated or 
Fc coated plates. Uncoated and Fc protein coated wells served as negative 
control in the experiment. Figure 2 shows that cells in CD137-Fc coated wells 
had a high release of IL-8, measuring almost up to 11ng/ml, whereas there was 
only about 2ng/ml of IL-8 detected in uncoated or Fc coated wells.  
To study the involvement of phospholipids in CD137L signalling in 
THP-1 cells, general inhibitors against SphK and PLD were used. DMS was 
used to inhibit SphK, and butan-1-ol was used to inhibit PLD. THP-1 cells 
were incubated with inhibitors for 15 minutes on ice. Subsequently, THP-1 
cells with and without pre-treatment of inhibitors were transferred into plates 
with immobilized CD137-Fc protein, or immobilized Fc protein or uncoated 
wells. Upon the addition of cells into the respective wells, the plates were 
incubated in the 37°C incubator for 24 hours. Supernatants were collected 
after 24 hours of incubation and subjected to IL-8 analysis using ELISA. 
For SphK inhibition studies, cells were pre-treated with 10µM of DMS. 
0.1% of DMSO was included as vehicle control because DMS is dissolved in 
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DMSO at 0.1% of total volume. This is to ensure that the effect seen is a true 
inhibition by inhibitors and not a toxic effect by the solvent DMSO.  
t-butanol was used as a negative control for non-specific effect caused 
by alcohol, namely butan-1-ol, which was used to inhibit PLD in cells.  
The amount of IL-8 production in THP-1 cells was significantly 
reduced by 10µM of DMS from 11ng/ml to about 3ng/ml as compared to 
vehicle control (Figure 2). However, 0.3% of butan-1-ol did not inhibit the 
production of IL-8 in the CD137L-activated cells (Figure 3).  
Next, we were interested to investigate if the SphK1 isoform plays a 
role in the activation of the cells upon cross-linking of the CD137L. 
Compound 5c, was shown to inhibit specifically SphK1 but not SphK2 (Wong 
et al., 2009). Two concentration of 5c were chosen for the subsequent assays; 
25µM and 50µM of 5c were selected to be used for the inhibition studies.  
There was no inhibition of IL-8 secretion in 25µM of 5c treated cells 
as compared to vehicle control (Figure 2). However, there was a substantial 
inhibition in the IL-8 secretion when cells were treated with 50µM of 5c. IL-8 
release was inhibited from 11ng/ml to about 5ng/ml when cells were treated 
with 50µM of 5c (Figure 2). The amount of IL-8 inhibited by 50µM of 5c is 
less than what was inhibited by 10µM of DMS; this may lead to the 
hypothesis that SphK2 may be responsible for part of the IL-8 production 
induced by the CD137L in THP-1 cells.  
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Figure 2. Sphingosine kinase inhibitors decrease CD137L-induced IL-8 
secretion. 1.5x10
4
 THP-1 cells were pre-incubated for 15 minutes with a final 
concentration of 10µM of DMS, 50µM or 25µM of compound 5c or the 
vehicle control (0.1% DMSO). Cells were then transferred into plates coated 
with Fc or CD137-Fc protein or uncoated plates for stimulation for 24 hours. 
Cells without any addition of inhibitors served as controls. IL-8 release was 
then determined by ELISA. Depicted are means ± standard deviations of 
triplicate measurements. Results are representative of 3 independent 


























Figure 3. Phopholipase D inhibitor, Butan-1-ol, did not show any inhibition in 
CD137L-induced THP-1 cell activation as shown by the release of IL-8. 
1.5x10
4
 THP-1 cells were pre-incubated for 15 minutes with a final 
concentration of 0.3% of butan-1-ol or control, 0.3% t-butanol. Cells were 
then transferred into plates coated with Fc or CD137-Fc protein or uncoated 
plates for stimulation for 24 hours. Cells without any addition of inhibitors 
served as controls. IL-8 releases were then determined by ELISA. Depicted 
are means ± standard deviations of triplicate measurements. Results are 
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3.3 Expression Of Sphingosine Kinase 1 In Monocytic Cell Lines 
Before proceeding to further investigations on the roles of SphK1 in 
CD137L-induced cells, we took a step back to look at the expression levels of 
SphK1 protein in the resting state of cells. The expression levels of SphK1 
protein in THP-1 cells and U-937 cells were analysed by Western Blot 
analysis. Equal amounts of total protein from the cell extracts were used from 
each cell line and were probed for SphK1. Figure 4 shows that SphK1 protein 
was present in both cell lines at comparable amounts. A housekeeping gene 
protein, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was used as 
loading control in the Western Blot. 
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Figure 4. Sphingosine kinase 1 was expressed in THP-1 cells and U-937 cells. 
Equal amounts of protein lysates were separated by SDS PAGE and blotted 
onto PVDF membrane. Blots were probed with rabbit anti-sphingosine kinase 
1 antibody (Cell Signaling Technology Inc., USA) overnight followed by anti-
rabbit IgG-HRP (Thermo Scientific, USA). GAPDH was used as loading 
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3.4 CD137L Signalling Activates Sphingosine Kinase 1 
THP-1 was shown to express SphK1 protein in amounts detectable by 
Western Blot analysis (Figure 4). But the presence of SphK1 protein does not 
imply that the enzyme is active in the cells. The measurement of enzyme 
activity is a more accurate way of investigating whether a protein plays a role 
in the signalling cascade upon cell activation. The sphingosine kinase activity 
was measured to determine if the enzyme activity was induced in THP-1 when 
CD137L was activated by the immobilized CD137-Fc protein.  
THP-1 cells were stimulated with immobilized CD137-Fc or Fc 
protein at time intervals from 2 to 30 minutes. Equal amounts of total cell 
lysates were used to investigate the sphingosine kinase activity. Figure 5 
shows that cross-linking of CD137L in THP-1 cells increased the sphingosine 
kinase activity as early as 5 minutes. The activity of the enzyme remained high 
until 30 minutes after stimulation. Sphingosine kinase activity reached its peak 
at 10 minutes with a 40% higher activity as compared to basal level. In this 
case, basal was defined as unstimulated or resting cells and was expressed as 
100% activity. The kinase activity was significantly higher at 10 minutes and 
30 minutes as compared to Fc control too. The enzyme activity remained 
around 20% above the basal level at 15 minutes and 30 minutes (Figure 5).    
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Figure 5. Cross-linking of CD137 ligand induced sphingosine kinase activity 
in THP-1 cells. 0.5x10
6
 THP-1 cells were seeded on CD137-Fc protein coated 
and Fc protein coated 12 well plates for stimulation for indicated times. Cells 
were lysed and equal amounts of protein lysates were used for each SphK 
activity measurement. The levels of sphingosine kinase activity at the 
indicated time points are expressed as percentage change over the basal level 
(0 minute). Basal level activity is expressed as 100%. Depicted are means ± 
standard deviations of triplicate measurements. Results are representative of 3 
independent experiments with comparable results. * p value < 0.05 between 
CD137-Fc stimulation at the indicated time points and basal level (0 minute). 
# p value < 0.05 between CD137-Fc stimulation and Fc control at the 
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3.5 CD137L Signalling Does Not Induce Sphingosine Kinase 1 Protein  
It has been shown that SphK1 protein expression is detectable by 
Western Blot analysis in THP-1 cell at the resting state (Figure 4). It has also 
been shown that SphK1 was involved in the production of the pro-
inflammatory chemokine, IL-8, within 24 hours after the cells were activated 
by CD137L signalling (Figure 2). Following up on these two sets of data, it 
was interesting to find out if activation of the CD137L signalling cascade in 
THP-1 cells would increase the level of SphK1 protein over 24 hours. THP-1 
cells were cultured on plates with immobilized CD137-Fc or Fc protein or on 
uncoated plates for 24 hours. Cells were collected and lysed for protein 
analysis by Western Blotting for SphK1. Cross-linking of CD137L on THP-1 
cells did not induce an increase of SphK1 protein expression in the cells after 
24 hours (Figure 6). SphK1 protein was shown to remain at the same level of 
expression, either in CD137-Fc stimulated or Fc control or unstimulated THP-









Figure 6. Sphingosine kinase 1 protein level remained unchanged after 24 
hours of cross-linking of CD137 ligand. THP-1 cells were cultured on 
uncoated (Un.) plates or on plates which were coated with Fc (Fc) or CD137-
Fc protein for 24 hours. Equal amounts of protein lysates were separated by 
SDS PAGE and blotted onto Polyvinylidene fluoride membrane. Blots were 
probed with rabbit sphingosine kinase 1 antibody (Cell Signaling Technology 
Inc., USA) overnight, followed by anti-rabbit IgG-HRP (Thermo Scientific, 
USA). GAPDH was used as loading control. Results are representative of 3 
independent experiments with comparable results. 
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3.6 Involvement Of Sphingosine Kinase In CD137L-Induced 
Inflammatory Chemokines Production 
IL-8, MCP-1, MIP-1α and MIP-1β belong to the inflammatory 
chemokine family. IL-8 is classified under the chemokine subfamily CXC 
chemokine, whereas MCP-1, MIP-1α and MIP-1β are classified under the 
chemokine subfamily CC chemokine (Deshmane et al., 2009; Zlotnik and 
Yoshie, 2012). As demonstrated above, IL-8 was secreted by THP-1 cells 
upon activation of CD137L (Figure 1). Next we moved on to investigate if 
other chemokines, namely MCP-1, MIP-1α and MIP-1β are secreted by 
CD137L-activated THP-1 cells. And, if they are produced by the stimulated 
cells, are they also being regulated by SphKs? 
Cross-linking of CD137 ligand is shown to induce the production of 
MCP-1 (Figure 7). About 1.3ng/ml of MCP-1 had been detected in the 
supernatants of CD137L-activated cells. However, this amount of cytokine 
was greatly reduced from 1.3ng/ml to 0.2ng/ml, 0.4ng/ml and 0.1ng/ml of 
MCP-1 when cells were pre-treated with 10µM of DMS, 25µM of 5c or 50µM 
of 5c respectively. These reductions of the MCP-1 release were significant as 
compared to vehicle control, DMSO.   
Activation of CD137 ligand signalling downstream not only induced 
the production of IL-8 and MCP-1 in the cells, but CD137L-activated cells 
were also producing MIP-1α (Figure 8) and MIP-1β (Figure 9). The secretion 
of both chemokines was suppressed by the SphK inhibitors, DMS and 5c. 
Cross-linking of CD137L on THP-1 cells produced about 2ng/ml of MIP-1α 
and this amount was reduced by 10µM of DMS, 25µM of 5c and 50µM of 5c 
to about 1ng/ml, 1.8ng/ml and 1.3ng/ml respectively (Figure 8).  
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About 1.4ng/ml of MIP-1β were secreted in CD137L-induced THP-1 
cells and this was also suppressed by the SphK inhibitors, DMS and 5c, to 
0.4ng/ml (by 10µM of DMS), 1.2ng/ml (by 25µM of 5c) and 0.7ng/ml (by 
50µM of 5c) (Figure 9).    
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Figure 7. Cross-linking of CD137 ligand induced the production of MCP-1. 
Sphingosine kinase inhibitors decrease the CD137L-induced MCP-1 secretion.  
1.5x10
4
 THP-1 cells were pre-incubated for 15 minutes with a final 
concentration of 10µM of DMS, 50µM or 25µM of compound 5c or the 
vehicle control (0.1% DMSO). Cells were then transferred into plates coated 
with Fc or CD137-Fc protein or uncoated plates for stimulation for 24 hours. 
Cells without any addition of inhibitors served as controls. MCP-1 release was 
then determined by ELISA. Depicted are means ± standard deviations of 
triplicate measurements. Results are representative of 3 independent 































Figure 8. Cross-linking of CD137 ligand induced the production of MIP-1. 
Sphingosine kinase inhibitors decrease the CD137L-induced MIP-1 secretion. 
1.5x10
4
 THP-1 cells were pre-incubated for 15 minutes with a final 
concentration of 10µM of DMS, 50µM or 25µM of compound 5c or the 
vehicle control (0.1% DMSO). Cells were then transferred into plates coated 
with Fc or CD137-Fc protein or uncoated plates for stimulation for 24 hours. 
Cells without any addition of inhibitors served as controls. MIP-1 release 
was then determined by ELISA. Depicted are means ± standard deviations of 
triplicate measurements. Results are representative of 3 independent 





























Figure 9. Cross-linking of CD137 ligand induced the production of MIP-1. 
Sphingosine kinase inhibitors decrease the CD137L-induced MIP-1 secretion. 
1.5x10
4
 THP-1 cells were pre-incubated for 15 minutes with a final 
concentration of 10µM of DMS, 50µM or 25µM of compound 5c or the 
vehicle control (0.1% DMSO). Cells were then transferred into plates coated 
with Fc or CD137-Fc protein or uncoated plates for stimulation for 24 hours. 
Cells without any addition of inhibitors served as controls. MIP-1 release 
was then determined by ELISA. Depicted are means ± standard deviations of 
triplicate measurements. Results are representative of 3 independent 
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3.7 Involvement Of Protein Kinase C In CD137 Ligand Signalling 
PKC is a very important mediator in signalling cascade in immune 
cells (Tan and Parker, 2003). IL-8 production induced by the CD137L 
signalling cascade in THP1 cells was halved by 500nM of the general PKC 
inhibitor; a total amount of 4ng/ml of IL-8 was reduced to 2ng/ml of IL-8 by 
Bis I as shown in Figure 10. The vehicle control, 0.1% DMSO, had no effect 
on the secretion of the IL-8 by the cells, implying that this reduction in IL-8 is 








Figure 10. Bisindolylmaleimide I decreases CD137L-induced IL-8 secretion. 
1.5x10
4
 THP-1 cells were pre-incubated for 30 minutes with a final 
concentration of 500nM of Bisindolylmaleimide I or the vehicle control (0.1% 
DMSO). Cells were then transferred into plates coated with Fc or CD137-Fc 
protein or uncoated plates for stimulation for 24 hours. Cells without any 
addition of inhibitors served as controls. IL-8 release was then determined by 
ELISA. Depicted are means ± standard deviations of triplicate measurements. 
Results are representative of 3 independent experiments with comparable 































4.1 CD137 Ligand Induced Adherence And Morphological Changes In 
THP-1 Cells 
Here, we have shown that THP-1 cells cultured in CD137-Fc coated 
plates had a higher percentage of adherent cells. THP-1 cells had shown 
morphological changes from round and spheric to elongated and a spread-out 
shape by 24 hours and continued to adapt to the elongated and spread-out by 
48 hours. Cells grown on Fc coated or uncoated plates did not have such 
changes. Both Langstein et al. (1999) and Söllner et al. (2007) showed that 
monocytes underwent morphological changes upon activation by CD137-Fc 
protein on the plates; morphological changes were found to be more 
pronounced in primary monocytes than in THP-1 cells (Langstein et al., 1998; 
Langstein and Schwarz, 1999; Söllner et al., 2007).  
In a separate experiment, cross-linking of CD137L by CD137-Fc 
protein induced adherence of THP-1 cells as early as 30 minutes and strong 
attachment was observed at 60 minutes. It was reassuring to observe cells to 
adhere to the CD137-Fc coated plates because this simply showed that 
CD137L on the THP-1 cell surface had bound to the CD137-Fc protein on the 
plate. This observation is in line with what was reported that CD137L 
activation causes increased cell adherence in monocytic cell line, THP-1, 
primary monocytes (Langstein et al., 2000; Langstein et al., 1998; Söllner et 
al., 2007), bone marrow-derived macrophages, murine myeloid cell line, 
RAW264.7 (Kim et al., 2009).   
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4.2 Involvement Of Sphingosine Kinases, Not Phospholipase D, In 
CD137 Ligand-Activated Cells  
CD137L-induced THP-1 cells secreted large amounts of the pro-
inflammatory chemokine, IL-8, at 24 hours and this is consistent with what 
was reported by literatures (Langstein et al., 2000; Langstein et al., 1998; 
Söllner et al., 2007). Around 11ng/ml of IL-8 were detected when cells were 
activated by CD137-Fc protein. IL-8 production was only detected around 
2ng/ml in Fc coated plates or uncoated plates; the effect of high release of IL-8 
is mainly due to the cross-linked CD137L on the monocytic cells.  
Our group has shown that CD137L reverse signalling in monocytes 
involves a few important classical kinases such as protein tyrosine kinase, 
MEK, MAPK p38, MAPK p44/42, PI3-K and PKA (Söllner et al., 2007). In 
this current study, the data that we have gotten so far suggest that SphK, 
particularly SphK1, is involved in the downstream signalling cascade in THP-
1 cells.  
DMS, a potent pharmacological inhibitor of SphK, inhibited around 70% 
of the total release of IL-8 induced by CD137L-activated THP-1 cells. The 
compound 5c was generated by Wong et al. (2009), and specifically targets 
the SphK1 isoform and not SphK2, also showed inhibition towards the 
secretion of IL-8 by CD137L-induced THP-1 cells (Wong et al., 2009). A 
lower dosage of 25µM of 5c did not affect the production of IL-8 by the cells; 
however, there is a significant drop in the IL-8 release when cells were treated 
with 50µM of 5c. Only 5ng/ml of IL-8 was detected in the supernatant of the 
cells pre-treated with 50µM of 5c.  
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DMS is a general inhibitor that is widely used to study the involvement 
of SphK. At 10µM, DMS is shown to be a competitive inhibitor to SphK only, 
and does not affect PKC activity (Edsall et al., 1998). In this study, the DMS 
concentration had been kept at 10µM in order not to affect other the activity of 
kinases, especially not PKC activity. However, perhaps a lower range of DMS 
concentration (2µM to 5µM) could be used in future experiments to minimise 
the side effects of the inhibitor; moreover, Edsall et al. (1998) had shown that 
SphK activity was reduced to 50% when DMS was used at 5µM (Edsall et al., 
1998). 10µM of DMS inhibited a higher percentage (~70%) of IL-8 release 
(from 11ng/ml to 3ng/ml) as compared to only ~55% inhibition by 50µM of 
5c (from 11ng/ml to 5ng/ml). The remaining 2ng/ml that was not inhibited by 
50µM of 5c may be contributed by the SphK2 isoform. But as whether the 
SphK2 is playing a compensatory role to the inhibited SphK1 or SphK2 is 
actually contributing to the production of IL-8 in the normal physiological 
condition, further investigation is needed to answer this question.  
PLD has been an important regulatory enzyme that catalyses 
phosphatidylcholine to yield another important second messenger, 
phosphatidic acid (PA), and choline. Sethu et al. (2008) have shown that 
PLD1 plays a major role in TNF-α signalling in monocytic cells, specifically 
U-937 and primary monocytes. TNF-α stimulation on monocytes activates 
PLD1, which subsequently activates SphK and calcium release. PLD1 is also 
demonstrated to play a part in cytokine release such as IL-1β and IL-6 (Sethu 
et al., 2008). This study had encouraged us to look at the possibilities that PLD 
may play a role in the CD137L signalling pathway given that CD137L and 
TNF-α belong to the same superfamily of TNF. If PLD is shown to also 
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contribute to the production of IL-8 in the CD137L signalling pathway, we 
would be wondering if PLD is also upstream of SphK as reported by Sethu et 
al. (2008). 
However, we have shown that 0.3% of butan-1-ol did not affect the 
release of IL-8 upon cross-linking of CD137L. This may imply that PLD is not 
activated by the reverse signalling of CD137L in THP-1 cells.       
There has always been a concern that CD137-Fc recombinant protein 
may activate Fc receptor (FcR) through its Fc portion of the protein, hence 
effect seen by CD137-Fc activation may be caused by the FcR. Melendez et al. 
(2001) showed that PLD1 is coupled to the activation of FcγR1 and 
subsequently activates SphK and transient release of calcium in U-937 cells 
(Melendez et al., 2001). In our studies, we showed that PLD is not involved in 
the downstream signalling cascade for IL-8 production upon CD137L 
stimulation in THP-1 cells. This may lend another supportive evident that the 
results that we have seen so far are mainly due to the CD137L activation, and 
not the FcR activation.     
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4.3 CD137L Does Not Induce Expression Of Sphingosine Kinase 1 
Under normal physiological conditions where cells are at a resting state, 
we have shown that SphK1 protein was present in THP-1 and U-937 cells. The 
amounts of SphK1 in the unstimulated cells are abundant in cytosol of both 
cell lines as also seen in macrophages (Melendez and Ibrahim, 2004).   
As shown by ELISA, CD137L activation induced high production of 
IL-8 and this is largely contributed to the SphK enzyme, particularly SphK1. 
DMS and 5c have markedly reduced the amount of this chemokine released by 
THP-1 cells upon the cross-linking of CD137L. Based on this observation, we 
were interested to find out if the readily available SphK1 in the cytosol is 
responsible for the whole production of IL-8 in the signalling pathway or do 
the cells produce more SphK enzyme in response to the activation of the 
CD137L signalling pathway. In other words, do the cells have a positive 
feedback mechanism to increase the amount of the enzymes in the cells to aid 
the chemokine production upon the activation of CD137L? 
CD137L activation did not induce SphK1 expression in THP-1 cells in 
24 hours culture. There is no increase of the amount of protein in the activated 
cells as compared to the untreated or Fc treated cells. Michel J. et al. (1999) 
have reported the same, that CD137L activation in lymphocytes did not induce 
higher expression of CD95 ligand (CD95L) in the Western Blot analysis in 24 
and 48 hours stimulation (Michel et al., 1999). Together, this may just indicate 
that CD137L activated cells do not activate the transcriptional machinery to 
produce proteins, be it SphK1 enzyme or CD95L, to drive an even more 
robust response within 24 hours.   
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4.4 CD137 Ligand Signalling Activates Sphingosine Kinase 1 
Stimulation of CD137L on THP-1 cells was shown to induce SphK 
activity. The SphK activity started to increase from 5 minutes reached its 
highest point at 10 minutes and remained higher than basal level even at 30 
minutes. Our results showed that SphK activity reached its peak at 10 minutes 
at 140% when compared to basal level which was expressed as 100%. The 
SphK enzyme remained active, its activity measured higher than 20% above 
basal level. This enzyme activity is found to be consistent with data from Xia 
et al. group (1999); the group was stimulating HUVEC with TNF-α for a 
longer time interval, measuring the activity up to 60 minutes (Xia et al., 1999). 
Xia et al. (1999) showed that SphK activity was induced by TNF-α in 
HUVEC. The SphK activity was also shown to reach its peak at 10 minutes, 
measuring higher than 150% and the enzyme remained active and higher than 
basal at 30 minutes. SphK activity was shown to only return to resting state 
activity at 60 minutes (Xia et al., 1999).  
In two other studies, SphK activities were shown to peak at earlier time 
point i.e. at 5 minutes instead. Xia et al. (1998) reported that TNF-α stimulated 
SphK activity in HUVEC, with its highest activity at 165% at 5 minutes 
interval. This observation was found to be accompanied by S1P production in 
the cells at the same time (Xia et al., 1998). Sethu et al. (2008) also showed 
that SphK activity peaked at 5 minutes, with a much higher activity after 
stimulation with TNF-α in U-937 and primary monocytes. SphK activity was 
higher than 200% and remained around that level for up to 30 minutes (Sethu 
et al., 2008).   
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4.5 Involvement Of Sphingosine Kinases In CD137 Ligand-Induced 
Inflammatory Chemokines Production 
MCP-1 (CCL2), as by the name of it, is a monocyte chemoattractant 
that mediates the migration and infiltration of monocytes or macrophages as a 
response to inflammation (Deshmane et al., 2009). Here, we have shown that 
cross-linking of CD137L in monocytes increased the release of MCP-1 at a 
substantial amount. From a basal level of less than 0.1ng/ml, CD137L-induced 
cells produced more than 1.3ng/ml of MCP-1 over 24 hours. Such an 
increment in the MCP-1 level is hypothesized to mediate the recruitment of 
monocytes to migrate to the site with higher levels of MCP-1, following its 
chemokine gradient.  
Ajuebor and co-workers (1998) have shown that in a murine 
inflammation model, administration of Zymosan into the peritoneal cavity 
attracted a huge number of polymorphonuclear leukocytes and monocytes to 
the site, mainly caused by the increase of MCP-1 (Ajuebor et al., 1998). They 
further confirmed this data by injection of murine recombinant MCP-1 protein 
into the peritoneal cavity, mimicking an artificial high secretion of MCP-1; 
this had specifically attracted migration of monocytes into the cavity. The 
migration of monocytes was significantly reduced to 40% when anti-mouse 
MCP-1 antibody was injected into the peritoneal cavity after the 
administration of Zymosan (Ajuebor et al., 1998).   
The production of MCP-1 by CD137L activation (~1.3ng/ml) was 
clearly suppressed by DMS and 5c. MCP-1 production was very sensitive to 
5c since at 25µM, MCP-1 secretion was inhibited to around 0.4ng/ml. For 
other chemokine profiles, namely IL-8, MIP-1α and MIP-1β, 25µM of 5c did 
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not reduce the releases significantly upon stimulation of CD137L. This may be 
an indication that especially MCP-1 production could be tightly regulated by 
SphK1 as shown in the data.  
In a cell-contact assay between fixed activated Jurkat T cells and U-
937 cells, Lai et al. (2008) showed that MCP-1 was secreted at a very high 
level (~9ng/ml) by the monocytic cell line (Lai et al., 2008). The same was 
observed when T lymphocytes derived from RA patients were cultured with 
autologous peripheral blood (PB) monocytes (MCP-1 secretion was about 
4ng/ml). This chemokine was shown to be inhibited by DMS. There was no 
sign of apoptosis observed in the inhibitor conditions, confirming that SphK1 
played a role in the MCP-1 production (Lai et al., 2008). 
High levels of MIP-1α and MIP-1β in terms of nanograms were 
detected in the supernatant of CD137L-activated cells. These chemokines 
were inhibited significantly by 10µM of DMS and 50µM of 5c. 25µM of 5c 
did not significantly reduce these chemokine levels. In the acute inflammatory 
peritoneal model by Ajuebor et al. (1998), MIP-1α was also reported to be 
elevated but the release was not affected by MCP-1 release. The chemokine 
was shown to only be secreted during inflammation (Ajuebor et al., 1998). 
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4.6 Involvement Of Protein Kinase C In CD137 Ligand Signalling 
It has previously been shown that Chelerythrine, a PKC specific 
inhibitor, did not inhibit production of IL-8 in primary monocytes and THP-1 
upon stimulation of CD137L (Söllner et al., 2007). The concentrations of 
Chelerythrine used were up to 3µM, but this inhibitor did not show any effect 
towards IL-8 secretion by the cells and it was also shown that at such high 
concentration, the inhibitor did not cause any reduction in cell viability 
(Söllner et al., 2007). However, in this present study, utilizing another 
commonly used PKC inhibitor, Bis 1, also known as GF109203X, we showed 
that IL-8 release initiated through the CD137L reverse signalling pathway is 
inhibited. Bis 1 inhibited the release of IL-8 by half.  
This is not surprising because a differential effect by different PKC 
inhibitors was also observed in IL-1α-induced chemokine (IL-8) release in 
synovial fibroblasts (Jordan et al., 1996). Jordan and co-worker (1996) 
reported that Chelerythrine chloride (concentration at 0.1 – 3µM) induced a 
slight increase in the mRNA and protein level of the chemokine. In the same 
study, this group has also shown that Bis 1 has a biphasic effects in IL-1α-
induced IL-8 release, that at low concentration (less than 3µM), Bis 1 caused 
higher chemokine release but at higher concentration (10 – 30µM), Bis 1 
effectively inhibited the chemokine production (Jordan et al., 1996). There are 
another two groups that reported lower concentration of Bis 1 is sufficient for 
PKC inhibition. 10µM of Bis 1 was sufficient to inhibit PMA-induced 
phosphorylation of Raf-1, a PKC target protein, substantially (Han et al., 2000) 
and at 2.5µM, Bis 1 could inhibit PMA-induced MAP Kinase Phosphatase-1 
(MKP-1) protein (Beltman et al., 1996). MKP-1 is an immediate early gene 
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product induced by growth factor. The inhibitory effect shown was not due to 
cell death because it was demonstrated that Bis 1 did not induce apoptosis in 
the cells up to 4 days of incubation (Han et al., 2000).    
There are two reports showing Chelerythrine does not inhibit PKC 
(Davies et al., 2000; Lee et al., 1998). Lee et al. (1998) reported that in their 
experimental set-up, Chelerythrine did not inhibit the PKC activity of calf 
brain at IC50=60-80µg/ml, it was shown that this compound stimulated PKC 
activity in the cytosol instead (Lee et al., 1998). In the same experimental set-
up, another PKC inhibitor, staurosoprine was shown to inhibit PKC activity 
very significantly (Lee et al., 1998).   
PKC has two functional moieties, the regulatory domain and the 
catalytic domain. Apart from different domain inhibition, enzyme inhibitors 
can be divided into competitive inhibitors and non-competitive inhibitors 
(Pajak et al., 2008). Chelerythrine was reported as a potent and specific 
inhibitor of PKC at IC50=0.66µM, acting on the substrate site of the PKC and 
not on the regulatory site of the kinase. It has been shown to be a competitive 
inhibitor to phosphate acceptor and a non-competitive inhibitor towards the 
ATP binding site. It does not block the phorbol esther binding to the PKC 
(Herbert et al., 1990; Pajak et al., 2008).  
On the other hand, Bis 1 inhibits PKC activity specifically at the ATP-
binding site as a competitive inhibitor against ATP. Bis 1 inhibits soluble and 
membrane forms of PKC and does not inhibit binding of [
3
H] phorbol 
dibutyrate to PKC (Pajak et al., 2008).  
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4.7 Cross-linking Is Needed To Activate The CD137L Signalling 
Pathway 
CD137-Fc is a recombinant fusion protein consisting of the 
extracellular domain of human CD137 linked to the constant domain of human 
IgG1 (Fc).  Immobilizing the CD137-Fc onto the plates for CD137L 
stimulation is critical and essential because Langstein et al. reported that 
soluble CD137-Fc was neither capable of inducing adherence of the cells on 
the plate (Langstein et al., 1998) nor the proliferation of the monocytes 
(Langstein et al., 1999). Soluble CD137-Fc protein is only capable of 
dimerization of the ligand on the cell surface through its Fc domain but not 
enough to achieve multimerization of the ligand (Langstein et al., 1999). 
Higher level of multimerization is needed to activate the ligand signalling 
cascade downstream. In order to achieve higher level of multimerization of the 
ligand, one can immobilize the protein onto the plate or cross-link the 
antibody with a secondary antibody. One may cross-link the CD137-Fc 
protein by the addition of anti-Fc antibody. An anti-Fc antibody is shown to be 
capable of cross-linking the ligand but to the lesser extent of the activation 
state by immobilizing the protein on the plate (Kang et al., 2007) 
Immobilizing the protein on the plate created a higher level of multimerization 
of the ligand, achieving the optimal activation of CD137L in the cells. 
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4.8 Controls In The Experiment 
Recombinant CD137 protein that is available commercially is fused to 
Fc portion of the immunoglobulin (referred as CD137-Fc in this thesis) in 
order to facilitate protein purification. Fcγ receptors (FcγR) are present on 
immune cells including monocytes and engagement of FcγR on monocytes 
can trigger downstream signalling pathways including PLD, PKC, PI3-K and 
MAPK (Jovanovic et al., 2009). FcγR has been reported to activate PLD and 
SphK (Melendez et al., 1998). As an additional control to eliminate the 
possibilities that Fc receptors on THP-1 cells are activated by the CD137-Fc 
protein, cells were first incubated with Fc blockers reagents to ensure that Fc 
receptors are blocked before cells were stimulated with CD137-Fc. Excessive 
Fc blocker reagents were washed away before cells were seeded onto the 
immobilized CD137-Fc or Fc protein wells.  
It is not unreasonable to include a negative control consisting of human 
IgG-Fc to eliminate any possibilities that the results obtained and analysed 
were the effects of the Fc protein and not the CD137 domain of the CD137-Fc 
protein. Uncoated plates were also used as negative control to observe the 
activities of untreated cell without any addition of proteins.  
As monocytes are heterogeneous in the culture, THP-1 cells were 
grown in low level of FBS (controlled at 1% v/v) media for 18 hours to 
synchronize the cells to the same phase i.e. G0 to obtain a homogenous culture 
for the experiments. 
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We showed that stimulation of CD137L induces adherence and 
morphological changes in THP-1 cells, and release of IL-8 as reported in the 
literature by several groups. We observed that cells had started to attach to the 
plate as early as 30 minutes and strong adherence was observed within 1 hour.  
Of the two phospholipid enzymes investigated, only SphK1, but not 
PLD plays a part in the release of IL-8. As shown, the SphK inhibitor DMS 
reduced IL-8 secretion from 11ng/ml to 3ng/ml whereas the SphK inhibitor 5c 
reduced IL-8 secretion from 11ng/ml to 5ng/ml. This observation led us to 
speculate that SphK2 may be involved in IL-8 production.  
CD137L stimulation activates SphK activity. SphK activity reached its 
peak after 10 minutes and maintained higher than basal level for up to 30 
minutes. However, CD137L stimulation does not increase the SphK1 protein 
level in the cells within 24 hours. 
CC chemokines favours the recruitment of monocytes (Cook, 1996; 
Deshmane et al., 2009). Stimulation of CD137L in THP-1 cells induces high 
production of CC chemokines, namely MCP-1, MIP-1α, MIP-1β. We 
suspected that the increase of these chemokines is mainly to attract monocytes 
into the inflamed tissues for a more robust inflammatory response. 
DMS and 5c substantially inhibit the secretion of MCP-1, MIP-1α and 
MIP-1β by THP-1 cells. Inhibition of the secretion of these chemokines 
indicates that SphK, particularly SphK1, is mediating the production of 
chemokines in the cells. MCP-1 secretion is significantly inhibited by a lower 
concentration of 5c, a hint that shows MCP-1 production may be tightly 
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regulated by SphK1. Targeting SphK in CD137L activated inflammation 
would be expected to reduce the release of inflammatory chemokines which in 
turn would reduce the influx of monocytes/macrophages. A reduction of 
leukocyte homing to the site of inflammation may decrease the inflammation 
severity especially in chronic inflammatory disease such as RA, 
atherosclerosis and etc.  
PKC is involved in production of IL-8 by CD137L stimulated THP-1 
cells as showed by the inhibition of IL-8 production when the PKC inhibitor 
Bis I was used. The fact that the PKC inhibitor Chelerythrine was previously 
shown not to inhibit the release of IL-8 was perhaps caused the ineffectiveness 
of Chelerythrine as a PKC inhibitor as reported by others. Figure C shows the 
proposed CD137L signalling pathway based on the findings by Söllner et al. 
(2007) and current findings in this study (Söllner et al., 2007).  
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Figure C. Proposed CD137L signalling pathway.  
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Dissecting the signalling cascade stimulated by CD137L is crucial to 
manipulate the molecules involved for the generation of novel therapeutic 
drugs, particularly to dampen excessive inflammation that may lead to 
autoimmune diseases. Phospholipid modifying enzymes like SphK that 
regulate immune responses triggered by CD137L are of most interest.  
In this project, SphK1 is identified as one of the key players in the 
release of chemokines. The next stage that we could go into would be to 
investigate the involvement of SphK in the regulation of the MAPK pathway 
and PI3-K pathway, and how SphK can affect the downstream signalling 
molecules in eliciting immune responses. It would be interesting to understand 
the mechanisms that are being employed by SphK. Is SphK involved in the 
regulation of the MAPK signalling pathway or is the MAPK the one 
responsible for the activation of SphK? How is SphK related to PKC in the 
CD137L reverse signalling, if there is any connection? NF-κB is responsible 
for the production of many cytokines and chemokines. Is this transcription 
factor also involved in the CD137L reverse signalling pathway? Or are there 
other transcription factors responsible for the production of the chemokines 
and cytokines?   
There is a possibility that SphK2 may also contribute to the effect of 
the reverse signalling of CD137L, either by compensating for the reduction of 
SphK1 activity, or it may be a normal physiological process that SphK2 is also 
involved in the chemokine production. Specific inhibitors for SphK2 such as 
ABC294640 could be used as valuable tools to understand the role of SphK2 
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in the reverse CD137L signalling in THP-1 cells. The two variants’ roles can 
be further confirmed by knocking down the genes using siRNA or antisense 
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ABSTRACT FOR CONFERENCE 
Role of Sphingosine Kinase in CD137L Signaling Pathway 
Background: CD137 (ILA/4-1BB), a member of tumour necrosis 
factor (TNF) receptor family, is a potent regulator of T cells activities. Both 
CD137 receptor and CD137 ligand (CD137L) are expressed as cell membrane 
proteins which allow bidirectional signalling. The signalling displayed by the 
CD137L is not well established especially the signalling mechanism and the 
molecules mediating it. It has been shown that cross-linking the CD137L 
induces proliferations, expression of M-CSF and the expression of several pro-
inflammatory cytokines such as IL6, IL8 and TNF-α. In this study, we 
investigated the signal transduction pathways triggered by CD137L on human 
monocytic cells, with particular emphasis on the role of sphingosine kinase 
(SphK). Our laboratory has shown that SphK is activated by several immune-
receptors, on various immune-effector cells, and that SphK mediates various 
pro-inflammatory responses. SphK phosphorylates sphingosine to 
sphingosine-1-phosphate and can be inhibited by the sphingosine-analogue 
N,N-dimethylsphingosine (DMS).  
Methods: CD137-Fc protein and anti-human 4-1BB ligand clone 5F4 
antibody were used to crosslink the CD137L on THP1 cells. 10µM of DMS 
were used to inhibit SphK activity. We measured the CD137L-mediated 
cytokine release (IL-8, IL-6) by ELISA, performed western blot for protein 
expression of IκB and phosphorylated p38 MAPK. We also analysed cell 
degranulation by measuring beta-hexosaminidase release. 
Results: Our findings showed that crosslinking CD137L triggers SphK 
activity and leads to the production of IL6 and IL8. Inhibition of SphK by 
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DMS inhibited the CD137L-triggered IL-6 production at 24 hours. 
Interestingly, the production of IL-8 was not inhibited by DMS. Western blot 
results showed that IκB is degraded following CD137L stimulation. 
Degradation of IκB is an indirect indicative of the activation of NF-κB. In 
cells pre-treated with DMS, there was a substantial inhibition on IκB 
degradation. Phosphorylated p38 was found to be inhibited by DMS. CD137L 
does not appear to trigger degranulation. 
Taken together the results presented here demonstrate that CD137L 
triggers intracellular signalling cascades in human monocytic cells, and 
suggest a key role for SphK in the signal transduction pathway leading to the 
activation of p38 MAPK, NF-κB and the subsequent production of IL-6 
production.  
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